

METHODS AND MATERIALS FOR EXAMINING PATHWAYS ASSOCIATED WITH GLIOBLASTOMA PROGRESSION

STATEMENT OF GOVERNMENT SUPPORT

5 [0001] This invention was made with support from U01 CA88127 from the National Cancer Institute/NIH and K08NS43147-01 from the National Institute of Neurological Disorders and Stroke/NIH. The government may have certain rights to this invention.

RELATED APPLICATIONS

10 [0002] This application claims priority under Section 119(e) from U.S. Provisional Application Serial No. 60/423,777 filed November 5, 2002, the contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

15 [0003] The present invention provides methods for the examination of biochemical pathways that are shown to be dysregulated in pathologies such as cancer and to reagents adapted for performing these methods.

BACKGROUND OF THE INVENTION

20 [0004] Cancers are the second most prevalent cause of death in the United States, causing 450,000 deaths per year. One in three Americans will develop cancer, and one in five will die of cancer. While substantial progress has been made in identifying some of the likely environmental and hereditary causes of cancer, there is a need for additional diagnostic and therapeutic modalities that target cancer and related diseases and disorders. In particular, there is for a need a greater understanding of the various biochemical pathways that are involved in dysregulated cell growth such as cancer as this will allow for the development of improved diagnostic and therapeutic methods for identifying and treating pathological syndromes associated with such growth
25 dysregulation.

30 [0005] Biochemical pathways that are of particular interest in pathologies such as cancer are the PI3K/Akt and Ras/MAPK pathways. Specifically, dysregulation of the PI3K/Akt and Ras/MAPK pathways occurs in many types of cancer (see, e.g., Vivanco et al., Nat Rev Cancer. 2: 489-501., 2002), including glioblastoma (GBM) (see, e.g.,
35 Vivanco et al., Nat Rev Cancer. 2: 489-501, 2002; Feldkamp et al., Journal of

Neurooncology 35: 223-248, 1997; Mischel et al., Brain Pathology, Jan;13(1):52-61 2003). Because constitutively activated signal transduction cascades directly modulate biological behavior, and because new molecular approaches to cancer therapy focus on inhibiting these pathways (see, e.g., Sawyers et al., Curr Opin Genet Dev. 12: 111-5, 2002; Druker et al., Cancer Cell. 1: 31-6., 2002; Kilic et al., Cancer Res. 60: 5143-50, 2000; Neshat et al., Proc Natl Acad Sci U S A. 98: 10314-9, 2001), it is critical that they be detected in patient biopsies. Traditionally, biochemical approaches such as Western blots and *in vitro* kinase assays have been required to assess activation of these pathways (see, e.g., Neshat et al., Proc Natl Acad Sci U S A. 98: 10314-9, 2001; Ermoian et al., Clin Cancer Res. 8: 1100-6, 2002). However, these techniques are not feasible on routinely processed tissues such as formalin-fixed, paraffin-embedded patient biopsy samples. Currently, the tools to identify activation pathways in patient biopsy material have not been fully developed. Development of such tools is critical to determine whether these pathway activations have prognostic significance, and to help stratify patients for targeted molecular therapy.

15 **[0006]** Glioblastoma multiforme (GBM), the most common malignant brain tumor of adults (and one of the most lethal of all cancers) is highly suited for this approach. GBMs have a set of defined molecular lesions with resultant signaling pathway disruptions. The tumor suppressor gene PTEN is altered in 30-40% of GBMs (see, e.g., Liu et al., Cancer Res. 57: 5254-7., 1997; Schmidt et al., J Neuropathol Exp Neurol. 58: 1170-83., 1999; Smith et al., J Natl Cancer Inst. 93: 1246-56., 2001). Since the PTEN lipid phosphatase activity negatively regulates activation of the Akt pathway and its downstream effectors mTOR, FKHR and S6 (see, e.g., Vivanco et al., Nat Rev Cancer. 2: 489-501., 2002), it is possible that PTEN protein deficient GBMs would show coordinated activation of this pathway. Primary GBMs (those that arise as *de novo* grade 25 IV tumors) also commonly over-express the oncogene EGFR, and its variant EGFRvIII, which activate signaling through both the RAS/MAPK and PI3K/Akt pathways. Therefore, it is also possible that EGFR and EGFRvIII expressing GBMs would show coordinate activation of the ERK and the Akt pathways. To date however, the relationship between these various pathways has not been delineated.

30 **[0007]** While researchers have identified a variety of genes and pathways involved in pathologies such as cancer, there is need in the art for additional tools to facilitate the analyses of the regulatory processes that are involved in dysregulated cell growth. Moreover, an understanding of how the products of genes involved in dysregulated cell growth interact in a larger context is needed for the development of

improved diagnostic and therapeutic methods for identifying and treating pathological syndromes associated with growth dysregulation. In particular, there remains a need to identify signal transduction events driving glioblastoma multiforme (GBM), and to identify markers useful for assessing progression or inhibition of GBM. The methods
5 and reagents disclosed herein satisfy this need.

SUMMARY OF THE INVENTION

[0008] Dysregulated activation of the PI3K/Akt pathway is common in cancers, including glioblastoma multiforme (GBM). Consequently, the assessment of this
10 pathway is critical for stratifying patients for targeted kinase inhibitor therapy. The disclosure provided herein identifies a series of biomarkers that are associated with dysregulated activation of the PI3K/Akt pathway as well as optimized methods for examining these markers. Consequently, the disclosure provided herein allows the examination of this pathway in cancers such as glioblastoma multiforme. Significantly,
15 the disclosed methods for examining these markers are useful with a wide variety of tissue samples including formalin fixed, paraffin embedded biopsy samples. Various aspects of this disclosure are described in Choe et al., Cancer Res. 2003 Jun 1;63(11):2742-6.

[0009] As disclosed herein, a series of PI3K/Akt pathway biomarkers associated
20 with cancers such as glioblastoma multiforme can be examined using for example a series of antibodies such as phospho-specific antibodies. In typical methods, a mammalian cell such as a cell derived from a formalin fixed, paraffin embedded glioblastoma multiforme biopsy sample can be examined for evidence of PI3K/Akt pathway activation by examining a tissue sample containing this cell for the presence of: a phosphorylated S6
25 polypeptide (SEQ ID NO: 1); a phosphorylated mTOR polypeptide (SEQ ID NO: 2); a phosphorylated FKHR polypeptide (SEQ ID NO: 3); a phosphorylated AKT polypeptide (SEQ ID NO: 4); a phosphorylated ERK polypeptide (SEQ ID NO: 8); or decreased levels of expression of the PTEN polypeptide (SEQ ID NO: 5), wherein the presence of a phosphorylated S6, mTOR, FKHR, AKT or ERK polypeptide, or
30 decreased levels of expression of the PTEN polypeptide, provides evidence of Akt pathway activation in the glioblastoma cell. Optionally the cell is examined for the presence of a plurality of characteristics such as a phosphorylated S6 polypeptide (SEQ ID NO: 1) and decreased levels of expression of the PTEN polypeptide (SEQ ID NO: 5). Certain embodiments of the invention comprise further methodological steps, the

step of using the results of the examination to identify and/or assess a therapeutic agent that may be used to treat the glioblastoma such as the step of using the results of the examination to evaluate the effect of an mTOR inhibitor such as rapamycin or an analogue thereof or an EGFR inhibitor such as ZD-1839 or an analogue thereof on a glioblastoma cancer cell.

[0010] A preferred embodiment of the invention is a method for identifying a mammalian glioma tumor likely to respond or responsive to an EGFR polypeptide (SEQ ID NO: 7) inhibitor or an mTOR polypeptide (SEQ ID NO: 2) inhibitor, the method comprising examining a sample obtained from the tumor for: the expression of PTEN polypeptide (SEQ ID NO: 5); and the presence of at least one of, a phosphorylated S6 ribosomal polypeptide (SEQ ID NO: 1); a EGFR polypeptide (SEQ ID NO: 7); a phosphorylated AKT polypeptide (SEQ ID NO: 4); and a phosphorylated ERK polypeptide (SEQ ID NO: 8), wherein decreased expression of PTEN polypeptide together with decreased phosphorylation of S6 ribosomal polypeptide in the sample, as compared to a control, identifies the glioma tumor as likely to respond or responsive to an mTOR inhibitor, and wherein decreased expression an of PTEN together with normal phosphorylation of S6 ribosomal polypeptide in the sample, as compared to a control, identifies the glioma tumor as not likely to respond or non-responsive to an mTOR inhibitor, and wherein normal or increased expression of PTEN and increased expression and/or activity of EGFR together with increased phosphorylation of AKT and/or phosphorylation of ERK identifies the glioma tumor as not likely to respond and/or non-responsive to an EGFR inhibitor.

[0011] Another embodiment of the invention is a kit for characterizing a mammalian glioma tumor or cell, the kit comprising: an antibody that binds PTEN (SEQ ID NO: 5); and/or an antibody that binds phosphorylated S6 ribosomal polypeptide (SEQ ID NO: 1); and/or an antibody that binds EFGR (SEQ ID NO: 7); and/or an antibody that binds phosphorylated AKT (SEQ ID NO: 4); and/or an antibody that binds phosphorylated ERK (SEQ ID NO: 8). Optionally the kit further includes an antibody that binds Ki-67 polypeptide (SEQ ID NO: 9), and/or p-H3 histone polypeptide (SEQ ID NO: 10) and/or caspase-3 polypeptide (SEQ ID NO: 11). Typically the kit further comprises a secondary antibody which binds to one of the primary antibodies directed to these polypeptides. Optionally the kit comprises a plurality of antibodies that bind to the various polypeptides.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 shows the immunohistochemical expression of PTEN, p-Akt, p-mTOR, p-FKHR and p-S6 in GBM tumor samples. (A) Representative images demonstrating PTEN protein loss in tumors cells with retention of staining in vascular endothelium (0), diminished PTEN staining relative to the endothelium (1), and no evidence of PTEN protein loss (2). NC is the negative control. (B) Staining for p-Akt, p-mTOR, p-FKHR and p-S6 scored on a scale of 2 (strong), 1 (mild) and 0 (negative). NC represents negative controls.

[0013] Figure 2 shows the immunohistochemical expression of EGFR, EGFRvIII and p-Erk in GBM tumor samples. (A) Representative images demonstrating diffuse EGFR, EGFRvIII and p-Erk positivity (+). Representative images of tumors lacking EGFR, EGFRvIII and p-ERK expression are also shown (-). NC represents the negative controls.

[0014] Figures 3A and 3B provide an illustration of the interaction between members of the PI3K/Akt pathway and kinase inhibitors in GBM tumor samples. Figure 3A shows that rapamycin inhibits S6 phosphorylation in glioblastoma in vivo. Figure 3B shows that the rapamycin-mediated inhibition of S6 phosphorylation correlates with diminished tumor proliferation. In this Figure, Ki-67, a marker of cellular proliferation was used to assess whether rapamycin-mediated inhibition of S6 had an effect on tumor growth.

DETAILED DESCRIPTION OF THE INVENTION

[0015] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995). As appropriate, procedures involving the use of commercially

available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted.

5 [0016] "Mammal" for purposes of treatment or therapy refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, *etc.* Preferably, the mammal is human.

 [0017] The terms "cancer", "cancerous", or "malignant" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to astrocytoma, blastoma, carcinoma, glioblastoma, leukemia, lymphoma and sarcoma. More particular examples
10 of such cancers include breast cancer, ovarian cancer, colon cancer, colorectal cancer, rectal cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, Hodgkin's and non-Hodgkin's lymphoma, testicular cancer, esophageal cancer, gastrointestinal cancer, renal cancer, pancreatic cancer, glioblastoma, cervical cancer, glioma, liver cancer, bladder cancer, hepatoma, endometrial carcinoma, salivary gland
15 carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.

 [0018] "Growth inhibition" when used herein refers to the growth inhibition of a cell *in vitro* and/or *in vivo*. The inhibition of cell growth can be measured by a wide variety of methods known in the art. A "growth inhibitory agent" when used herein
20 refers to a compound or composition which inhibits growth of a cell *in vitro* and/or *in vivo*. Thus, the growth inhibitory agent may be one which significantly reduces the percentage of cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and
25 vinblastine), TAXOL®, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Such agents further include inhibitors of cellular pathways associated with dysregulated cell
30 growth such as the PI3K/Akt pathway. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995).

[0019] "Treatment" or "therapy" refer to both therapeutic treatment and prophylactic or preventative measures. The term "therapeutically effective amount" refers to an amount of a drug effective to treat a disease or disorder in a mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (*i.e.*, slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (*i.e.*, slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the disorder. To the extent the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy, efficacy *in vivo* can, for example, be measured by assessing tumor burden or volume, the time to disease progression (TTP) and/or determining the response rates (RR).

[0020] The term "antibody" is used in the broadest sense and specifically covers single monoclonal antibodies and antibody compositions with polyepitopic specificity (e.g. polyclonal antibodies) as well as antibody fragments so long as retain their ability to immunospecifically recognize a target polypeptide epitope.

[0021] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (see, *e.g.*, U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the

techniques described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991), for example.

5 [0022] As used herein, the term "polynucleotide" means a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA and/or RNA. In the art, this term is often used interchangeably with "oligonucleotide". A polynucleotide can comprise a nucleotide sequence disclosed herein wherein thymidine (T) can also be uracil (U); this definition pertains to the differences between the chemical structures of DNA and RNA,
10 in particular the observation that one of the four major bases in RNA is uracil (U) instead of thymidine (T).

[0023] As used herein, the term "polypeptide" means a polymer of at least about 10 amino acids. Throughout the specification, standard three letter or single letter designations for amino acids are used. In the art, this term is often used interchangeably
15 with "protein".

[0024] As used herein, the term "inhibitor" encompasses molecules capable of inhibiting one or more of the biological activities of target molecules such as mTOR and/or EGFR polypeptide. Illustrative inhibitors include the targeted small-molecule inhibitors and antibody inhibitors disclosed herein as well as other inhibitors known in
20 the art such as anti-sense polynucleotides and siRNA. Consequently one skilled in the art will appreciate that such inhibitors encompass molecules which inhibit both polynucleotide synthesis and/or function (e.g. antisense polynucleotide molecules) as well those which inhibit polypeptide synthesis and/or function (e.g. molecules which block phosphorylation and hence activity of a target polypeptide such as mTOR).

25

Physiological Processes Pertinent To The Invention

[0025] The disclosure provided herein identifies a series of biomarkers that are associated with deregulated activation of the PI3K/Akt pathway, a pathway whose deregulated activation is common in cancers such as gliomas. The disclosure provided
30 herein further provides optimized methods for examining these biomarkers. Consequently, the disclosure allows the examination of the activation status of these biomarkers in cancers such as glioblastoma multiforme. Significantly, the disclosed methods for examining these biomarkers are useful with a wide variety of tissue samples including formalin fixed, paraffin embedded biopsy samples. As disclosed herein, these

markers can be examined using a panel of antibodies such as phospho-specific antibodies. In these methods, a mammalian cell such as a cell derived from a formalin fixed, paraffin embedded glioblastoma multiforme biopsy sample can be examined for evidence of Akt pathway activation by examining a tissue sample containing this cell for the presence of the various target molecules disclosed herein including phosphorylated polypeptides. Certain embodiments of the invention identify and/or assess a therapeutic agent that may be used to treat the glioblastoma such as rapamycin or an analogue thereof or an EGFR inhibitor such as ZD-1839 or an analogue thereof.

[0026] As noted above, the invention disclosed herein provides methods and immunohistochemical reagents that can be used to identify the activation state of the PI3K/Akt signaling pathway in clinical samples such as glioblastoma biopsy samples. These methods and reagents identify a coordinate regulation of the Akt/mTOR signaling pathway in response to loss of the PTEN tumor suppressor gene. As specific kinase inhibitors that target this pathway are currently in development (see, e.g., Neshat et al., Proc Natl Acad Sci U S A. 98: 10314-9, 2001), and further because this mutation is common in glioblastoma and prostate cancer, this disclosure provides an important clinical tool for selecting patients for appropriate therapy. In this context, the invention can be practiced by performing immunohistochemical analysis on routinely processed patient biopsy samples. The results of these assays can be used as criteria for inclusion in clinical trials, and to assess outcome differences in patients in which this pathway is deregulated.

[0027] The methods and reagents disclosed herein can be used to determine the activation state of biomarker polypeptides such as Akt and its downstream effectors such as mTOR, ERK, Forkhead and S6-kinase on routinely processed patient biopsy samples (e.g. glioblastoma samples) and this information can be used to select patients for therapy with targeted pathway inhibitors. As disclosed herein, the invention has been tested on a tissue microarray derived from biopsies from 48 glioblastoma patients. The results demonstrate clear coordinate regulation of Akt, mTOR, forkhead and S6-kinase, and their association with PTEN loss. A detailed discussion of the biomarkers and the physiological processes pertinent to the invention is provided below.

[0028] Activation of PI3K by growth factor signaling catalyzes the formation of phosphatidylinositol triphosphate (PIP3) by addition of a phosphate group to phosphoinositol bisphosphate (PIP2). PIP3 catalyzes the activation of the Akt kinase (and its downstream effectors mTOR, forkhead and S6-kinase), which promote cell

proliferation and survival. The PTEN tumor suppressor gene encodes a phosphatase that removes the phosphate group from PIP3, thereby regulating the activation state of this pathway. PTEN loss results in constitutive signaling through PIP3, and hence unregulated activation of the Akt pathway.

5 **[0029]** PTEN is lost in many types of cancer including glioblastomas and cancers of the prostate. In addition, the Akt pathway is dysregulated in many other cancers. PTEN-deficient cancer cells are dramatically more sensitive to inhibition of the Akt pathway at the level of mTOR (see, e.g., Neshat et al., Proc Natl Acad Sci U S A. 98: 10314-9, 2001), than PTEN wild-type cells, including non-cancerous cells. Therefore, 10 mTOR inhibitors can be a highly selective and effective therapy for patients whose tumors have PTEN loss and Akt pathway activation. All prior knowledge of the PTEN/PI3K/Akt pathway is based on biochemical data and genomic analysis, which are not feasible as a clinical screening tool. Currently, there are no methods for detection of the activation state of this pathway in routinely processed formalin-fixed, paraffin- 15 embedded patient biopsy samples. Consequently, the ability to identify the activation state of this pathway in such clinical samples, and to select patients for its inhibition is a valuable diagnostic tool. This is also valuable tool for the analyses of inhibitors that target this pathway.

[0030] As specifically disclosed herein we demonstrate that PI3'K/Akt pathway 20 activation can be detected in routinely processed GBM patient biopsies. We demonstrate that PTEN loss is significantly correlated with Akt activation, which is significantly associated with activation of downstream effectors mTOR, S6 and FKHR. We have also shown that PTEN loss is not the only mechanism of PI3'K/Akt pathway activation, and demonstrated that EGFR and EGFRvIII co-expression are significantly 25 associated with activation of this pathway. Finally, we demonstrate that PI3K/Akt and Erk pathway activation have significant impact on GBM patient progression and survival. These data provides evidence that this set of tools can be used to stratify GBM patients for targeted molecular therapy.

[0031] The epidermal growth receptor factor receptor contributes to the 30 malignant phenotype of human glioblastomas (see, e.g. Thomas et al., Int J Cancer. 2003 Mar 10;104(1):19-27). Studies in SKMG-3 cells, a GBM cell line that maintains EGFR gene amplification in vitro demonstrate that EGF treatment stimulated phosphorylation of the EGFR as well as the downstream effectors Erk, AKT1, stat3 and c-Cbl. Under minimal growth conditions, unstimulated SKMG-3 cells contain constitutively

phosphorylated Erk and AKT1. The EGFR kinase inhibitor PD158780 reduces the constitutive phosphorylation of the receptor and Erk but not that of AKT1. In contrast, inhibition of phosphatidylinositol-3-kinase (PI3K) blocks the constitutive phosphorylation of Erk and AKT-1 but not the EGFR. The results provide evidence
5 that signals from overexpressed EGFR contribute to the constitutive phosphorylation of Erk, but these signals may not required for the constitutive activation of PI3K or AKT1. See, e.g. Thomas et al., *Int J Cancer*. 2003 Mar 10;104(1):19-27.

[0032] In addition, EGFR appears to play an important role in the pathogenesis of colorectal cancer as shown for example by studies of the EGFR tyrosine kinase
10 inhibitor ZD1839 in metastatic colorectal cancer patients in which serial biopsies were taken pre- and posttreatment to assess biological activity (see, e.g. Daneshmand *Clin Cancer Res*. 2003 Jul;9(7):2457-64). In these studies, paired biopsies were obtained from colorectal cancer patients before and after treatment. Posttreatment samples showed a statistically significant reduction in cancer cell proliferation. While all pretreatment
15 samples showed strong staining for EGFR, loss of immunohistochemical staining for activated EGFR, phosphorylated Akt, and phosphorylated ERK in cancer cells was observed in some patients after treatment. See e.g., Daneshmand *Clin Cancer Res*. 2003 Jul;9(7):2457-64.

[0033] The PI3'K/Akt pathway is commonly deregulated in GBMs, but its
20 identification in routine biopsies has presented a challenge. In the face of new kinase inhibitors that target this pathway, the need for an assay that can be used to stratify patients for therapy has become critical. As disclosed herein, we demonstrate that activation of the PI3'K/Akt pathway can be detected by immunohistochemistry using a panel of phospho-specific antibodies. We show that 38% of untreated primary GBMs
25 demonstrate evidence of PTEN protein loss, and that this is significantly associated with Akt activation. We further demonstrate that phosphorylation of Akt is significantly correlated with phosphorylation of downstream effectors mTOR, FKHR and S6. We show that PTEN loss is not the only mechanism underlying Akt pathway activation; phosphorylation of Akt, mTOR, S6 and FKHR are also associated with co-expression of
30 EGFR and its constitutively active variant EGFRvIII. Finally, we demonstrate that activation of the PI3'K/Akt and Erk pathways is associated with shorter time to progression and diminished overall survival in GBM patients.

[0034] The disclosure provided herein demonstrates that PI3'K/Akt pathway activation can be detected in paraffin-embedded biopsy samples, and provides evidence

that PTEN loss is highly correlated with Akt pathway activation in primary GBMs. These results also provide evidence that co-expression of EGFR and EGFRvIII can activate the PI3'K pathway in GBMs with normal PTEN immunohistochemical expression. The results further provide evidence that activation of these signaling pathways has considerable impact on GBM patient progression and survival.

[0035] The disclosure provided herein specifically demonstrates that the activation of the PI3'K/Akt pathway can be detected with phospho-specific antibodies in routinely processed patient biopsies. We show that PTEN-deficient GBMs have coordinated activation of the Akt pathway and its downstream effectors mTOR, FKHR and S6. We also show that GBMs co-expressing EGFR and EGFRvIII have activation of the PI3'K/Akt and Erk signaling pathways. Finally, we demonstrate that activation of these signal transduction pathways has prognostic importance. For example, primary GBM patients whose tumors are activated downstream of Akt, or at the level of ERK, have significantly shorter time to tumor progression and significantly diminished overall survival. These results define molecular subtypes of GBMs and may be used to stratify patients for targeted molecular therapy.

[0036] As disclosed in detail below, in illustrative analytical methods we generated a tissue microarray from 45 untreated primary GBM patient biopsies and analyzed the immunohistochemical expression of p-Akt and downstream effectors p-mTOR, p-FKHR and p-S6, as well as p-Erk. EGFR, EGFRvIII expression, and PTEN loss, all of which can promote activation of the PI3'K/Akt pathway, were also analyzed and association with PI3'K/Akt and Erk pathway activation were determined. The prognostic implications of PI3'K/Akt and Erk pathway activation were also analyzed.

[0037] In our analysis the loss of PTEN immunohistochemical expression was detected in 38% of GBMs. Diminished PTEN protein expression was significantly associated with phosphorylation of Akt ($p<0.00001$) and downstream effectors mTOR ($p=0.04$), FKHR ($p=0.006$) and S6 ($p=0.001$). PTEN protein loss was not associated with Erk activation, which is independent of PI3'K/Akt signaling. PTEN protein loss was not the only route to PI3'K/Akt pathway activation; co-expression of EGFR and EGFRvIII was significantly correlated with expression of p-Akt ($p=0.06$), p-mTOR ($p=0.001$), p-FKHR ($p=0.002$) and p-S6 ($p=0.001$) in GBMs with normal PTEN protein expression. EGFR and EGFRvIII co-expression was also associated with Erk activation ($p=0.007$). Concurrent phosphorylation of mTOR, FKHR and S6, was significantly

associated with shorter time to progression ($p=0.002$) and decreased overall survival ($p=0.02$), as was Erk activation ($p=0.04$).

[0038] As noted above, the methods disclosed herein typically employ immunohistochemical analysis. Immunohistochemical analysis requires a subjective determination by pathologists. Proteomic approaches have the potential to be a more objective and sensitive methods and may become clinically feasible in the future (see, e.g., Liotta et al., *Jama*. 286: 2211-4., 2001; Liotta et al., *Breast Cancer Res.* 2: 13-4, 2000; Petricoin et al., *Lancet*. 359: 572-7., 2002; Petricoin et al., *Nat Rev Drug Discov.* 1: 683-95., 2002). However, the current need to stratify patients for targeted therapy, and to assess molecular correlates of response to experimental targeted agents, dictates that we develop assays that work on routinely processed biopsy samples using currently accessible methods. Activated Akt can be detected by immunohistochemistry done on patient biopsies, and it has been suggested that it may have biological or prognostic implications (see, e.g., Gupta et al., *Clin Cancer Res.* 8: 885-92., 2002; Malik et al., *Clin Cancer Res.* 8: 1168-71., 2002). Complementary to previous studies, we demonstrate here that a panel of phospho-specific antibodies can be used to detect p-Akt and its downstream effectors in order to map PI3'K/Akt pathway activation. The high level of association between the downstream effector activation and Akt phosphorylation, provides evidence that we have accurately assessed this pathway. Further, our data showing that PI3'K/Akt pathway activation is associated with PTEN protein loss (see, e.g., Neshat et al., *Proc Natl Acad Sci U S A.* 98: 10314-9., 2001; Ermoian et al., *Clin Cancer Res.* 8: 1100-6., 2002) or EGFR/EGFRvIII signaling, are highly consistent with recent *in vitro* and in animal models (see, e.g., Davies et al., *Cancer Res.* 59: 2551-6., 1999; Davies et al., *Cancer Res.* 58: 5285-90., 1998; Lorimer et al., *Biochim Biophys Acta.* 1538: 1-9., 2001; Moscatello et al., *J Biol Chem.* 273: 200-6., 1998), including a recent biochemical demonstration that PTEN protein level is inversely correlated with Akt activation in GBM patient biopsies (see, e.g., Ermoian et al., *Clin Cancer Res.* 8: 1100-6., 2002).

[0039] Our finding that ERK and PI3'K/Akt pathway activation were associated with shorter time to progression and decreased overall survival is the first demonstration that pathway activation may have an impact on GBM patient prognosis. The data presented herein provides evidence that pathway activation status conveys important prognostic information. It is surprising that Akt activation was not significantly associated with progression or survival, while downstream activation at the

level of mTOR, S6 and FKHR was. This result raises two possibilities. Either the p-Akt antibody is a less sensitive tool for detecting PI3'K/Akt pathway activation than is the panel of downstream phospho-specific antibodies. Alternatively, convergent inputs to mTOR, FKHR and S6 downstream of Akt, or in and Akt-independent fashion, may play an important role in modulating the biological behavior of GBMs. In line with this, concurrent Erk and Akt-mediated signaling may be required for optimal activation of p70 S6 kinase, and formation of p-S6 (see, e.g., Iijima et al., J Biol Chem. 277: 23065-75., 2002; Shi et al., J Biol Chem. 277: 15712-20., 2002). Similarly, Akt-independent mechanisms of mTOR and FKHR phosphorylation have been demonstrated (see, e.g., Gingras et al., Genes and Development. 15: 807-826., 2001; Burgering et al., Trends Biochem Sci. 27: 352-60., 2002). Using the disclosure provided herein and methods typically employed in the art one can determine whether these additional inputs play a role in modulating GBM behavior. For additional discussions of EGFR and Akt activity and inhibitors thereof, see, e.g. Bianco et al., Oncogene, 2003 May 8;22(18):2812-22; Yakes et al., Cancer Res. 2002 Jul 15;62(14):4132-41; and She et al., Clin Cancer Res. 2003 Oct 1;9(12):4340-6, the contents of which are incorporated herein by reference

[0040] While the sample size of 45 patients is relatively modest, it was large enough to provide robust associations between PTEN loss and PI3'K/Akt pathway activation. Only untreated primary GBM patients were included in this study. Since treatment itself may modulate Erk and PI3'K/Akt pathway activation, this study design enabled us to better assess the association between pathway activation and upstream molecular events. Using the disclosure provided herein and methods typically employed in the art one can perform both retrospective, and prospective analyses of GBM patients (both treated and untreated) to further quantify the prognostic implications of pathway activation and to identify molecular correlates of response to therapy.

[0041] In order to address any subjectivity of immunohistochemical analysis all immunostains were interpreted independently by two neuropathologists, and by one of the neuropathologists at independent occasions, and the inter-rater and intra-rater agreement were high for all stains. This provides evidence that interpretation of these phospho-specific antibodies will be reproducible between independent pathologists. In the future, more objective methods such as proteomic analysis can replace these tools (see, e.g., Liotta et al., Jama. 286: 2211-4., 2001; Petricoin et al., Nat Rev Drug Discov. 1: 683-95., 2002). Nonetheless, the data presented here provides evidence that we can

accurately assess these pathways using currently available methods, and provides evidence that one can stratify patients for therapy.

[0042] GBMs are among the most heterogeneous tumors, as has been previously shown (see, e.g., Cheng et al., *J Neuropathol Exp Neurol.* 58: 120-8., 1999; Jung et al., *J Neuropathol Exp Neurol.* 58: 993-9., 1999). This poses a problem for assessment of molecular alterations in GBMs, as well as for stratification of patients for targeted inhibitor therapy. Using the disclosure provided herein and methods typically employed in the art one can directly determine the extent of intra-tumor molecular heterogeneity for PTEN, EGFR and EGFRvIII and assess the impact of this on pathway activation, prognosis and response to therapy.

[0043] The methods of the invention are applicable to a wide variety of cancers where dysregulation of the PI3K/Akt pathway is associated with a concurrent dysregulation in cellular growth. As noted above, typical embodiments of the invention examine cellular pathways in the family of tumors termed "gliomas". Briefly, the brain contains two major cell types: neurons and glia. Glial cells give rise to the family of tumors termed "gliomas". There are several distinct types of tumors within this glioma grouping. These can range from very benign, slow-growing tumors to rapidly enlarging, highly malignant cancerous types. The most commonly occurring tumors within the glioma family are astrocytomas, oligodendroglioma and ependymomas. In addition, some patients may have tumors with a mixed appearance. Astrocytomas are the most common type of glioma. These are tumors that occur within the brain tissue itself. Like all gliomas, astrocytomas can be located either superficially or deep within the brain and can affect critical structures. As they arise from the astrocyte cells (which serve as supporting elements of the brain), astrocytomas are generally infiltrative in nature.

[0044] As discussed in detail below, the World Health Organization (WHO) grading scheme is used to characterize this group of tumors. Briefly, in the World Health Organization grading system, grade I tumors are the least malignant. These tumors grow slowly and microscopically appear almost normal; surgery alone may be effective. Grade I tumors are often associated with long-term survival. Grade II tumors grow slightly faster than grade I tumors and have a slightly abnormal microscopic appearance. These tumors may invade surrounding normal tissue, and may recur as a grade II or higher tumor. Grade III tumors are malignant. These tumors contain actively reproducing abnormal cells and invade surrounding normal tissue. Grade III tumors frequently recur, often as grade IV tumors. Grade IV tumors are the most malignant and invade wide

areas of surrounding normal tissue. These tumors reproduce rapidly, appear very unusual microscopically and are necrotic (have dead cells) in the center. Grade IV tumors cause new blood vessels to form, to help maintain their rapid growth. Glioblastoma multiforme is the most common grade IV tumor. For additional information see, e.g.

- 5 Tatter SB , Wilson CB, Harsh GR IV. Neuroepithelial tumors of the adult brain. In Youmans JR, ed. Neurological Surgery, Fourth Edition, Vol. 4: Tumors. W.B. Saunders Co., Philadelphia, pp. 2612-2684, 1995; Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathology 3:255-68, 1993; Lopes MBS, VandenBerg SR, Scheithauer BW; The World Health Organization classification of
10 nervous system tumors in experimental neuro-oncology. In A.J. Levine and H.H. Schmidek, eds. Molecular Genetics of Nervous System Tumors Wiley-Liss, New York, pp. 1-36, 1993.

[0045] Low-grade astrocytomas (Grades I/IV or II/IV) are termed benign and occur generally in children or young adults. These tumors carry a better prognosis than
15 higher grade astrocytomas. Although the management of these low-grade astrocytomas can be controversial, those tumors which are surgically accessible are usually resected. One of the concerns with low-grade astrocytomas in adults is that they can undergo a malignant transformation and change into a higher-grade, or malignant tumor. The methods of the invention can be used to monitor such transformations. In astrocytomas
20 grade I, normal karyotype is observed most frequently; among the cases with abnormal karyotypes, the most frequent chromosomal abnormalities loss of the X and Y sex-chromosomes; loss of 22q is found in 20-30% of astrocytomas; other abnormalities observed in low grade tumors include gains on chromosome 8q, 10p, and 12p, and losses on chromosomes 1p, 4q, 9p, 11p 16p, 18 and 19.

25 [0046] Anaplastic astrocytomas (Grade III/IV) are more aggressive tumors and, as such, are usually treated in a more radical fashion. In anaplastic astrocytomas, chromosome gains or losses are frequent: trisomy 7 (the most frequent), loss of chromosome 10, loss of chromosome 22, loss of 9p, 13q; other abnormalities, less frequently described are: gains of chromosomes 1q, 11q, 19, 20, and Xq.

30 [0047] Glioblastoma multiforme (Grade IV/IV) is the most malignant form of astrocytomas. Although these tumors can occur at almost any age, the peak incidence is between 50 and 70 years old. Glioblastoma multiforme (GBM) is also called a high-grade glioma and is graded by pathologists as Grade IV/IV astrocytoma. These tumors mostly occur in adults with the peak incidence between 50 and 70 years of age. Generally

the time from the onset of symptoms to diagnosis is relatively short, usually just a few weeks. Glioblastomas typically show several chromosomal changes: by frequency order, gain of chromosome 7 (50-80% of glioblastomas), double minute chromosomes, total or partial monosomy for chromosome 10 (70% of tumors) associated with the later step in the progression of glioblastomas partial deletion of 9p is frequent (64% of tumors): 9pter-23; partial loss of 22q in 22q13 is frequently reported loss or deletion of chromosome 13, 13q14-q31 is found in some glioblastomas trisomy 19 was reported in glioblastomas by cytogenetic and comparative genomic hybridization (CGH) analysis; the loss of 19q in 19q13.2-qter was detected by loss of heterozygosity (LOH) studies in glioblastomas deletion of chromosome 4q, complete or partial gains of chromosome 20 has been described; gain or amplification of 12q14-q21 has been reported the loss of chromosome Y might be considered, when it occurs in addition to other clonal abnormalities.

[0048] Oligodendrogliomas are benign, slow growing tumors that occur usually in young adults. Often these are located within the frontal lobes which can allow for a safe, complete operative resection. Many oligodendrogliomas contain calcium (little specks of bone) seen best on CT scans.

[0049] Certain embodiments of the invention include methods to obtain information used to identify a therapeutic agent for treating a cancer such as a glioblastoma in a human. For example, methods of the invention examine the levels of certain polypeptides (e.g. PTEN) and/or the phosphorylation state of certain polypeptides (e.g. S6) to obtain information on how the cancer cell will respond to rapamycin or a rapamycin analog. Rapamycin (also known as sirolimus or rapammune) is a macrolide, related to cyclosporin with immunosuppressive properties and antiproliferative activity in various human tumor cells lines and tumor xenograft models. Both rapamycin and rapamycin analogues with more favorable pharmaceutical properties, such as SDZ-RAD, CCI-779, RAD 001, Everolimus (Certican) and AP23573, are highly specific inhibitors of mTOR. As noted herein the mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway that mediates cell survival and proliferation, and consequently is a target for anticancer therapeutic development. In essence, rapamycin and rapamycin analogues gain function by binding to the immunophilin FK506 binding protein 12 and the resultant complex inhibits the activity of mTOR. Because mTOR activates both the 40S ribosomal protein S6 kinase (p70s6k)

and the eukaryotic initiation factor 4E-binding protein-1, rapamycin-like compounds block the actions of these downstream signaling elements, which results in cell cycle arrest in the G1 phase. Rapamycin and its analogues also prevent cyclin-dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which potentially contribute to the prominent inhibitory effects of rapamycin at the G1/S boundary of the cell cycle. Rapamycin and rapamycin analogues have demonstrated impressive growth-inhibitory effects against a broad range of human cancers. For example, as noted herein, mammalian target of rapamycin (mTOR) modulates key signaling pathways that promote uncontrolled proliferation of glioblastoma multiforme. In this context the methods of the invention can be used to examine the PI3K/Akt pathway and then select an appropriate therapeutic agent in cells having a deregulated PI3K/Akt pathway (e.g. rapamycin). For discussions of Rapamycin and its analogs, see, e.g. Mita et al., Clin Breast Cancer 2003 Jun;4(2):126-37; Hosoi et al., Mol Pharmacol. 1998 Nov;54(5):815-24; Hidalgo et al., Oncogene. 2000 Dec 27;19(56):6680-6; Alexandre et al., Bull Cancer. 1999 Oct;86(10):808-11; and Eshleman et al., Cancer Res. 2002 Dec 15;62(24):7291-7.

[0050] Overexpression of epidermal growth factor receptor (EGFR) is also observed in a wide variety of cancers such as glioma and has frequently been correlated with poor prognosis; thus stimulating efforts to develop new cancer therapies that target EGFR. Monoclonal antibodies and tyrosine kinase inhibitors specifically targeting EGFR are the most well-studied and hold substantial promise of success. Several compounds of monoclonal antibodies and tyrosine kinase inhibitors targeting EGFR have been studied and clinical trials are now underway to test the safety and efficacy of these targeting strategies in a variety of human cancers. Compounds that target the extracellular ligand-binding region of EGFR include antibodies such as Cetuximab (also known as Erbitux or IMC-C225). Other compounds such as tyrosine kinase inhibitors which target the intracellular domain of EGFR, include ZD-1839 (also known as gefitinib or Iressa), OSI-774 (also known as Erlotinibor or Tarceva), PD-153053, PD-168393 and CI-1033, have been studied in clinical settings alone or in combination with radiation or chemotherapy. In addition, compounds such as h-R3, ABX-EGF, EMD-55900 and ICR-62 have proved to be effective in targeting malignant cells alone or in combination with traditional therapies. The effects of ZD 1839 (Iressa) is currently being studied in clinical trails for patients with glioblastoma multiforme. In this context

the methods of the invention can be used to examine the PI3K/Akt pathway and then select an appropriate therapeutic agent in cells that do not have a deregulated PI3K/Akt pathway (e.g. an EGFR inhibitor). For discussions of EGFR inhibitors see, e.g. Khalil et al., *Expert Rev Anticancer Ther.* 2003 Jun;3(3):367-80; Chakravarti et al., *Int J Radiat Oncol Biol Phys.* 2003 Oct 1;57(2 Suppl):S329; Wissner et al., *Bioorg Med Chem Lett.* 2002 Oct 21;12(20):2893-7; Ciardiello et al., *Expert Opin Investig Drugs*, 2002 Jun;11(6):755-68; De Bono et al., *Trends Mol Med.* 2002;8(4 Suppl):S19-26; and Cohen, *Clin Colorectal Cancer.* 2003 Feb;2(4):246-51.

10 Typical Methods of the Invention

[0051] The invention disclosed herein has a number of embodiments. Illustrative embodiments of the invention include methods which examine tumor samples such as formalin fixed, paraffin embedded glioblastoma multiforme biopsy samples for evidence of deregulated activation of the PI3K/Akt pathway. These methods involve examining the presence and/or phosphorylation status of the disclosed biomarkers that are associated with this pathway in order to identify and/or assess a therapeutic agent that may be useful in the treatment of a glioblastoma. As disclosed herein, the presence and/or phosphorylation status of the disclosed biomarkers serves as a marker or proxy of pathway activity.

20 [0052] Typically, the methods of the invention are used in evaluating the whether a tumor such as a glioma is likely to respond (i.e. is likely to exhibit growth inhibition) when contacted with an mTOR inhibitor or an EGFR inhibitor. In such embodiments, the presence and/or phosphorylation status of a biomarker polypeptide that is associated with the activation of a pathway (e.g. a phosphorylated S6 ribosomal polypeptide (SEQ ID NO: 1)) is examined to determine if the pathway is dysregulated in that tumor and is therefore susceptible to inhibition by an inhibitor known to target that pathway. In such embodiments, the tumor is examined prior to its exposure to the inhibitor. Alternatively, the methods evaluate whether a tumor such as a glioma is responsive (i.e. exhibits growth inhibition) to an mTOR inhibitor or an EGFR inhibitor. In such embodiments, the activity of a biomarker polypeptide that is associated with the activation of a pathway (e.g. a phosphorylated S6 ribosomal polypeptide (SEQ ID NO: 1)) is examined after the tumor is exposed to the inhibitor to determine if the biomarkers in the pathway respond to exposure to the inhibitor.

[0053] One such embodiment of the invention is a method for identifying a mammalian glioma (e.g. glioblastoma multiforme) tumor likely to respond, is responsive to an EGFR polypeptide (SEQ ID NO: 7) inhibitor or an mTOR polypeptide (SEQ ID NO: 2) inhibitor, the method comprising examining a sample obtained from the tumor for: the expression of PTEN polypeptide (SEQ ID NO: 5); and the presence of at least one of, a phosphorylated S6 ribosomal polypeptide (SEQ ID NO: 1); a EGFR polypeptide (SEQ ID NO: 7); a phosphorylated AKT polypeptide (SEQ ID NO: 4); and a phosphorylated ERK polypeptide (SEQ ID NO: 8), wherein decreased expression of PTEN polypeptide together with decreased phosphorylation of S6 ribosomal polypeptide in the sample, as compared to a control, identifies the glioma tumor as likely to respond or responsive to an mTOR inhibitor, and wherein decreased expression an of PTEN together with normal phosphorylation of S6 ribosomal polypeptide in the sample, as compared to a control, identifies the glioma tumor as not likely to respond or non-responsive to an mTOR inhibitor, and wherein normal or increased expression of PTEN and increased expression and/or activity of EGFR together with increased phosphorylation of AKT and/or phosphorylation of ERK identifies the glioma tumor as not likely to respond and/or is non-responsive to an EGFR inhibitor. Optionally, the phosphorylation of S6 ribosomal polypeptide is determined subsequent to contacting the tumor or sample with an mTOR inhibitor and/or the phosphorylation of AKT and/or ERK is determined subsequent to contacting the tumor or sample with an EGFR inhibitor. In illustrative embodiments, the mTOR inhibitor is rapamycin, SDZ-RAD, CCI-779, RAD 001, or AP23573 and the EGFR inhibitor is ZD-1839, OSI-774, PD-153053, PD-168393, IMC-C225 or CI-1033.

[0054] In typical methods, the expression of the biomarker polypeptides is examined using an antibody such as an antibody that binds an epitope comprising a phosphorylated serine residue at position 235 in SEQ ID NO: 1, an antibody that binds an epitope comprising a phosphorylated serine residue at position 473 in SEQ ID NO: 4, or an antibody that binds an epitope comprising a phosphorylated threonine residue at position 202 and tyrosine 204 in SEQ ID NO: 8. Optionally, the sample is a paraffin embedded biopsy sample.

[0055] Another embodiment of the invention is a method for identifying a mammalian glioma tumor that does not express a PTEN polypeptide (SEQ ID NO: 5) and which is not likely to respond or is nonresponsive to an inhibitor of mTOR polypeptide (SEQ ID NO: 2) activity, the method comprising examining a sample

obtained from the tumor for the presence of phosphorylated S6 ribosomal polypeptide (SEQ ID NO: 1) after contacting the tumor or the sample with the inhibitor, wherein, an observable decrease in phosphorylated S6 ribosomal polypeptide in the sample, as compared to a control that is not contacted with the inhibitor identifies the glioma tumor as likely to respond or responsive to the inhibitor, and wherein no observable decrease in phosphorylated S6 ribosomal polypeptide in the sample, as compared to a control identifies the glioma tumor as not likely to respond or nonresponsive to the inhibitor.

[0056] Yet another embodiment of the invention is a method for identifying a mammalian glioma tumor that expresses a PTEN polypeptide (SEQ ID NO: 5) and which is not likely to respond or is nonresponsive to an inhibitor of EGFR polypeptide (SEQ ID NO: 7) activity, the method comprising examining a sample obtained from the tumor for the presence of EGFR (SEQ ID NO: 7) and the presence of a phosphorylated AKT polypeptide (SEQ ID NO: 4) or the presence of a phosphorylated ERK polypeptide (SEQ ID NO: 8) after contacting the tumor or the sample with the inhibitor, wherein an increase in the levels of the EGFR polypeptide and the levels of phosphorylated AKT polypeptide or phosphorylated ERK polypeptide identifies the glioma tumor as not likely to respond or nonresponsive to the inhibitor. Optionally, the sample obtained from the tumor is examined for the presence of a phosphorylated AKT polypeptide (SEQ ID NO: 4) and the presence of a phosphorylated ERK polypeptide (SEQ ID NO: 8).

[0057] As noted above, certain embodiments of the invention include the examination of the expression of a polypeptide or phosphorylation of a polypeptide. As is known in the art, the examination of such polypeptide expression and polypeptide phosphorylation status in a cell or tissue sample is typically evaluated as compared to a control, i.e. a control cell and/or tissue sample that has a defined or predetermined level of polypeptide expression or phosphorylation. In an example of polypeptide phosphorylation, a control can be a normal tissue (e.g. non cancerous glial cells) where it is observed that a polypeptide is typically not phosphorylated. In an example of polypeptide expression, Example 3 and Figure 2 provided illustrative examples of the methods of the invention using such controls, in particular, a PTEN expression grading system known the art that uses vascular endothelium as a control. Specifically PTEN immunohistochemical staining (which is directly correlated with PTEN expression) is scored according to an established scale of 0-2, in which the vascular endothelium (score of 2) serves as an internal control. Tumor cells are graded as 2 if their staining intensity

is equal to that of the vascular endothelium, 1 if it is diminished relative to the vascular endothelium, and 0 if it is undetectable in the tumor cells and present in the vascular endothelium. This scoring system, which has been shown to be highly consistent between different cancer cell types, including gliomas (as disclosed herein) and cancers of the breast, ovary, pancreas and colon, allows artisans to readily examine the expression levels of PTEN polypeptides in a sample such as a formalin fixed, paraffin embedded biopsy sample.

5 [0058] Additional embodiments of the invention include a method for identifying a mammalian glioblastoma multiforme cancer cell that does not express a PTEN polypeptide (SEQ ID NO: 5) and which is likely to exhibit growth inhibition when contacted with an inhibitor of mTOR polypeptide (SEQ ID NO: 2) activity, the method comprising examining the cancer cell for the presence of phosphorylated S6 ribosomal polypeptide (SEQ ID NO: 1) after contacting the cancer cell with the inhibitor, wherein, an observable decrease in phosphorylated S6 ribosomal polypeptide in the sample, as compared to a control mammalian glioblastoma multiforme cancer cell that is not contacted with the inhibitor identifies the cancer cell as likely to exhibit growth inhibition when contacted with the inhibitor, and further wherein no observable decrease in phosphorylated S6 ribosomal polypeptide in the sample, as compared to a control mammalian cell identifies the cancer cell as not likely to exhibit growth inhibition when contacted with the inhibitor. In these methods, the inhibitor of mTOR polypeptide activity is optionally rapamycin, CCI-779, RAD 001, or AP23573. Typically, the expression of the PTEN polypeptide or the presence of phosphorylated S6 ribosomal polypeptide is examined using an antibody that binds the PTEN polypeptide or the phosphorylated S6 ribosomal polypeptide (e.g. an antibody that binds an epitope comprising a phosphorylated serine residue at position 235 in SEQ ID NO: 1). Preferably, the mammalian glioblastoma multiforme cancer cell is obtained from a paraffin embedded biopsy sample.

20 [0059] Another embodiment of the invention is a method for identifying a mammalian glioblastoma multiforme cancer cell that expresses a PTEN polypeptide (SEQ ID NO: 5) and which is not likely to exhibit growth inhibition when contacted with inhibitor of EGFR polypeptide (SEQ ID NO: 7) activity, the method comprising examining the cancer cell for the presence of EGFR (SEQ ID NO: 7), the presence of a phosphorylated AKT polypeptide (SEQ ID NO: 4) or a the presence of a phosphorylated ERK polypeptide (SEQ ID NO: 8), wherein an increase in the levels of

the EGFR polypeptide and the levels of phosphorylated AKT polypeptide or phosphorylated ERK polypeptide identifies the cancer cell as not likely to exhibit growth inhibition when contacted with inhibitor of the EGFR polypeptide. In these methods, the inhibitor of EGFR activity is optionally ZD-1839, OSI-774, PD-153053, PD-168393
5 or CI-1033. Typically, the expression of the PTEN polypeptide or the presence of EGFR polypeptide is examined using an antibody that binds the PTEN polypeptide or the EGFR polypeptide. Optionally, the presence of phosphorylated AKT is examined using an antibody that binds an epitope comprising a phosphorylated serine residue at position 473 in SEQ ID NO: 4 and the presence of phosphorylated ERK is examined
10 using an antibody that binds an epitope comprising a phosphorylated threonine residue at position 202 or a phosphorylated tyrosine residue at position 204 in SEQ ID NO: 8. In illustrative methods, the mammalian glioblastoma multiforme cancer cell is obtained from a paraffin embedded biopsy sample.

[0060] Another embodiment of the invention is a method for determining the
15 responsiveness of a mammalian glioblastoma cell to a growth inhibitory agent selected from the group consisting of a EGFR polypeptide (SEQ ID NO: 7) inhibitor or an mTOR polypeptide (SEQ ID NO: 2) inhibitor, the method comprising examining the glioblastoma cell for the presence of a S6 polypeptide (SEQ ID NO: 1) having a phosphorylated serine, threonine or tyrosine residue; a mTOR polypeptide (SEQ ID
20 NO: 2) having a phosphorylated serine, threonine or tyrosine residue; a FKHR polypeptide (SEQ ID NO: 3) having a phosphorylated serine, threonine or tyrosine residue; a AKT polypeptide (SEQ ID NO: 4) having a phosphorylated serine, threonine or tyrosine residue; a ERK polypeptide (SEQ ID NO: 8) having a phosphorylated serine, threonine or tyrosine residue; or the expression of the PTEN polypeptide (SEQ ID NO:
25 5), wherein the presence of a phosphorylated S6, mTOR, FKHR, AKT or ERK polypeptide, or decreased levels of expression of the PTEN polypeptide in the glioblastoma cell relative to a control mammalian vascular endothelial cell determines the responsiveness of the mammalian glioblastoma cell to the growth inhibitory agent. Optionally in such methods, the mammalian glioblastoma cell has been contacted with
30 the growth inhibitory agent. Alternatively, the mammalian glioblastoma cell has not been contacted with the growth inhibitory agent.

[0061] Yet another embodiment of the invention is a method to obtain information used to identify a therapeutic agent for treating glioblastoma in a human, the method comprising examining a glioblastoma cell obtained from the human for the

presence of: a S6 polypeptide (SEQ ID NO: 1) having a phosphorylated serine, threonine or tyrosine residue; a mTOR polypeptide (SEQ ID NO: 2) having a phosphorylated serine, threonine or tyrosine residue; a FKHR polypeptide (SEQ ID NO: 3) having a phosphorylated serine, threonine or tyrosine residue; a AKT polypeptide (SEQ ID NO: 4) having a phosphorylated serine, threonine or tyrosine residue; or decreased levels of expression of the PTEN polypeptide (SEQ ID NO: 5), wherein the presence of a phosphorylated S6, mTOR, FKHR or AKT polypeptide, or decreased levels of expression of the PTEN polypeptide in the glioblastoma cell provides information used to identify a therapeutic agent for treating the glioblastoma in the human. Optionally in this method, the glioblastoma cell is examined for the presence of a plurality of these characteristics. In one such embodiment, the glioblastoma cell is examined for the presence of a S6 polypeptide (SEQ ID NO: 1) having a phosphorylated serine, threonine or tyrosine residue and decreased levels of expression of the PTEN polypeptide (SEQ ID NO: 5). Optionally the glioblastoma cell is in a paraffin embedded biopsy sample.

[0062] As noted above, embodiments of the invention typically utilize antibodies that specifically bind phosphorylated polypeptides, i.e. polypeptides having a phosphorylated serine, threonine or tyrosine residue. In this context the disclosure provides antibodies that bind to specific epitopes comprising a phosphorylated residue (e.g. serine at position 2481 in SEQ ID NO: 2). By utilizing antibodies that bind to an epitope that comprises a phosphorylated residue (i.e. phospho-specific antibodies) but which do not bind to the unphosphorylated form of the same polypeptide, these phospho-specific antibodies can be used to examine the activation status of a pathway, where the activation is associated with phosphorylation of one or more specified residues. In certain embodiments of the invention, the phosphorylation status and/or expression levels of multiple members of a signalling pathway (e.g. S6 and mTOR) are examined as a confirmatory assessment of the signalling cascade associated with the pathway.

[0063] Certain embodiments of the invention are used with formalin fixed, paraffin embedded biopsy samples. In particular, the disclosure provided herein demonstrates that antibodies such as phospho-specific antibodies can be used with antigen samples processed in this manner. Significantly, the disclosure provided herein further demonstrates that the methods using these samples provide an accurate demonstration of the physiological status of the pathways in these samples.

Consequently, the disclosure provided herein demonstrates how the methods of the invention are well suited for use with commonly available clinical samples.

5 **[0064]** In one illustrative embodiment of the invention, the presence of a S6 polypeptide (SEQ ID NO: 1) having a phosphorylated serine, threonine or tyrosine residue is examined using an antibody that binds an epitope comprising a phosphorylated serine residue at position 235 in SEQ ID NO: 1. In another illustrative embodiment of the invention, the presence of a mTOR polypeptide (SEQ ID NO: 2) having a phosphorylated serine, threonine or tyrosine residue is examined using an antibody that binds an epitope comprising a phosphorylated serine residue at position 2481 in SEQ ID
10 NO: 2. In another illustrative embodiment of the invention, the presence of a FKHR polypeptide (SEQ ID NO: 3) having a phosphorylated serine, threonine or tyrosine residue is examined using an antibody that binds an epitope comprising a phosphorylated threonine residue at position 24 in SEQ ID NO: 3. In another illustrative embodiment of the invention, the presence of a AKT polypeptide (SEQ ID NO: 4) having a
15 phosphorylated serine, threonine or tyrosine residue is examined using an antibody that binds an epitope comprising a phosphorylated serine residue at position 473 in SEQ ID NO: 4. The expression levels and/or phosphorylation of additional polypeptide markers can also be examined. Illustrative example of such additional markers include Ki-67 (SEQ ID NO: 9) and p-H3 histone H3 (SEQ ID NO: 10).

20 **[0065]** Yet another embodiment of the invention is a method of examining a mammalian cell for evidence of Akt pathway activation comprising examining the mammalian cell for the presence of: a S6 polypeptide (SEQ ID NO: 1) having a phosphorylated serine residue at position 235 in SEQ ID NO: 1; a mTOR polypeptide (SEQ ID NO: 2) having a phosphorylated serine residue at position 2481 in SEQ ID
25 NO: 2; a FKHR polypeptide (SEQ ID NO: 3) having a phosphorylated threonine residue at position 24 in SEQ ID NO: 3; a AKT polypeptide (SEQ ID NO: 4) having a phosphorylated serine residue at position 473 in SEQ ID NO: 4; or decreased levels of expression of the PTEN polypeptide (SEQ ID NO: 5), wherein the presence of a phosphorylated S6, mTOR, FKHR or AKT polypeptide, or decreased levels of
30 expression of the PTEN polypeptide evidence of Akt pathway activation in the mammalian cell. Optionally the mammalian cell is examined for the presence of a plurality of characteristics such as a S6 polypeptide (SEQ ID NO: 1) having a phosphorylated serine residue at position 235 in SEQ ID NO: 1 and decreased levels of

expression of the PTEN polypeptide (SEQ ID NO: 5). Typically in this method, the mammalian cell is a cancer cell such as a cancer cell is of a glioblastoma lineage.

5 **[0066]** Certain embodiments of the invention comprise further methodological steps, for example using the results of the examination in a prognostic determination of tumor progression and/or using the results of the examination to identify the presence of a glioblastoma characterized by a short time from initial diagnosis to patient death. Optionally the further methodological steps include the step of using the results of the examination to identify a therapeutic agent for treating the glioblastoma such as the step of using the results of the examination to evaluate the effect of rapamycin on the glioblastoma cancer cell. Optionally the mammalian cell is in a paraffin embedded biopsy sample.

15 **[0067]** A preferred embodiment of the invention is a method of examining a mammalian cell for evidence of Akt pathway activation comprising using a phospho-specific antibody to examine the cell for the presence of a phosphorylated protein in the mammalian cell selected from the group consisting of mTOR, FKHR and S6, wherein the presence of a phosphorylated mTOR, FKHR or S6 protein in the mammalian cell provides evidence of Akt pathway activation. In highly preferred embodiments, the cell is examined for the concurrent phosphorylation of mTOR, FKHR S6 proteins. Such methods typically include an optional step of using a phospho-specific antibody to examine the cell for evidence of phosphorylation of a Akt protein in the mammalian cell. In such methods, the mammalian cell is typically a cancer cell that is present in a paraffin embedded biopsy sample. In highly preferred embodiments of the invention the cancer cell is of the glioblastoma lineage.

25 **[0068]** Yet another embodiment of the invention is a method of examining a mammalian cell for evidence of Erk pathway activation comprising using a phospho-specific antibody to examine the cell for presence of phosphorylated p-44/42 MAP kinase proteins in the cells, wherein the presence of phosphorylated p-44/42 MAP kinase proteins in the mammalian cell provides evidence of Erk pathway activation. In preferred methods, the mammalian cell is present in a paraffin embedded biopsy sample obtained from an individual suspected of suffering from glioblastoma.

30 **[0069]** Another embodiment of the invention is a method of examining a tissue sample for the presence of mammalian glioblastoma cells having a phenotype characterized by a shorter time to tumor progression comprising using phospho-specific antibodies to examine the cell for the presence of phosphorylated mTOR, FKHR and S6

proteins in the cells, wherein the presence of a phosphorylated mTOR, FKHR and S6 proteins in the mammalian cell provides evidence of the phenotype. A related embodiment of the invention is a method of examining a tissue sample for the presence of mammalian glioblastoma cells having a phenotype characterized by a short time from initial diagnosis to patient death comprising using phospho-specific antibodies to examine the cell for the presence of phosphorylated mTOR, FKHR and S6 proteins in the cells, wherein the presence of a phosphorylated mTOR, FKHR and S6 proteins in the mammalian cell provides evidence of the phenotype.

[0070] Another embodiment of the invention is a method of examining a tissue sample for the presence of mammalian glioblastoma cells having a phenotype characterized by a shorter time to tumor progression comprising using a phospho-specific antibody to examine the cell for the presence of phosphorylated Erk proteins in the cells, wherein the presence of a phosphorylated Erk proteins in the mammalian cell provides evidence of the phenotype. A related embodiment of the invention is a method of examining a tissue sample for the presence of mammalian glioblastoma cells having a phenotype characterized by a short time from initial diagnosis to patient death comprising using phospho-specific antibodies to examine the cell for the presence of phosphorylated p-44/42 MAP kinase proteins in the cells, wherein the presence of a phosphorylated p-44/42 MAP kinase proteins in the mammalian cell provides evidence of the phenotype.

[0071] Yet another embodiment of the invention is a method of obtaining information useful for identifying an appropriate therapeutic agent to use to treat an individual suffering from glioblastoma comprising examining a tissue sample from the patient for the presence of glioblastoma cells having a phosphorylated protein selected from the group consisting of mTOR, FKHR and S6, wherein the presence of a phosphorylated mTOR, FKHR or S6 protein in the mammalian cell provides information useful for identifying an appropriate therapeutic agent to use to treat an individual suffering from glioblastoma. In preferred embodiments of the invention the mammalian cell is examined for the presence of at least two and more preferably three phosphorylated proteins selected from the group consisting of mTOR, FKHR and S6. Typically the therapeutic agent is a kinase inhibitor of the Akt pathway.

[0072] Another embodiment of the invention is a method of obtaining information useful for identifying an appropriate therapeutic agent to use to treat an individual suffering from glioblastoma comprising examining a tissue sample from the

patient for the presence of glioblastoma cells having phosphorylated Erk proteins, wherein the presence of phosphorylated Erk proteins in the mammalian cell provides information that can be used to identify an appropriate therapeutic agent to use to treat an individual suffering from glioblastoma.

5 **[0073]** Another embodiment of the invention is a method of examining a mammalian cell for evidence of Akt pathway activation comprising examining the cell for the expression of the EGFR and the EGFRvIII proteins, wherein the coexpression of the EGFR and the EGFRvIII proteins in the cell provides evidence of Akt pathway activation. A related embodiment of the invention is a method of examining a
10 mammalian cell for evidence of Erk pathway activation comprising examining the cell for the expression of the EGFR and the EGFRvIII proteins, wherein the coexpression of the EGFR and the EGFRvIII proteins in the cell provides evidence of Erk pathway activation. Yet another embodiment of the invention is a method of examining a mammalian glioblastoma cell for evidence of Akt pathway activation, wherein the
15 mammalian glioblastoma cell is obtained from a paraffin embedded biopsy sample, the method comprising examining the cell for decreased expression of the PTEN protein, wherein a decrease in the expression of the PTEN protein cell provides evidence of Akt pathway activation.

20 Articles of Manufacture of the Invention

[0074] Embodiments of the invention also include articles of manufacture and/or kits designed to facilitate the methods of the invention. Typically such kits include instructions for using the elements therein according to the methods of the present invention. Such kits can comprise a carrier means being compartmentalized to
25 receive in close confinement one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method. For example, one of the container means can comprise one or more of the antibodies disclosed herein (an anti-S6 antibody for example) that is or can be detectably labeled with a marker. For kits utilizes immunological methods (e.g.
30 immunohistochemistry and Western blotting) to detect the target proteins, the kit can also have containers containing buffers for these methods and/or containers comprising antibodies labelled with a reporter-means, such as a chromophore or radioactive molecule. In addition, for kits which utilize additional methodologies such as caspase-3

assays or tunel assays of apoptosis, additional reagents associated with these techniques can be further included in the kits.

5 **[0075]** In a typical embodiment of the invention, an article of manufacture containing materials useful for the examination of the disorders described above is provided. The article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container can hold a composition (e.g. an antibody composition) which is effective for examining mammalian cells (e.g. glioblastoma cells). The label on, or associated with, the container
10 indicates that the composition is used for examining cellular polypeptides. The article of manufacture may further comprise a second container comprising a buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

15 **[0076]** One such embodiment of the invention is a kit comprising at least one antibody selected from the group consisting of: an antibody that binds a S6 polypeptide (SEQ ID NO: 1), wherein the S6 polypeptide epitope bound by the antibody comprises a phosphorylated serine, threonine or tyrosine residue; an antibody that binds a mTOR polypeptide (SEQ ID NO: 2), wherein the mTOR polypeptide epitope bound by the
20 antibody comprises a phosphorylated serine, threonine or tyrosine residue; an antibody that binds a FKHR polypeptide (SEQ ID NO: 3), wherein the FKHR polypeptide epitope bound by the antibody comprises a phosphorylated serine, threonine or tyrosine residue; and an antibody that binds a AKT polypeptide (SEQ ID NO: 4), wherein the AKT polypeptide epitope bound by the antibody comprises a phosphorylated serine,
25 threonine or tyrosine residue; and wherein the kit further includes instructions for using the antibody to examining a mammalian cell for evidence of AKT pathway activation. Optionally the kit further comprises an antibody that binds a PTEN polypeptide (SEQ ID NO: 5). The kits of the invention can further include antibodies to additional polypeptides such as Ki-67 (SEQ ID NO: 9) and p-H3 histone H3 (SEQ ID NO: 10).

30 **[0077]** Another embodiment of the invention is a kit comprising an antibody capable of immunospecifically binding a phosphorylated protein in a mammalian cell selected from the group consisting of phosphorylated Akt, mTOR, FKHR and S6 proteins and instructions for using the antibody to examining the mammalian cell for evidence of Akt pathway activation. In preferred methods, the kit comprises different

antibodies, each of which is capable of immunospecifically binding 2, 3 or 4 phosphorylated proteins in a mammalian cell selected from the group consisting of phosphorylated Akt, mTOR, FKHR and S6 proteins. Another embodiment of the invention is a kit comprising an antibody capable of immunospecifically binding a phosphorylated p-44/42 MAP kinase proteins in a mammalian glioblastoma cell present in a paraffin embedded biopsy sample and instructions for using the antibody to examining the mammalian cell for evidence of Erk pathway activation.

[0078] Yet another embodiment of the invention is a kit for characterizing a mammalian glioblastoma (GBM) tumor or cell, the kit comprising: an antibody that binds PTEN (SEQ ID NO: 5) and at least one of the following: an antibody that binds phosphorylated S6 ribosomal protein (SEQ ID NO: 1); an antibody that binds EFGR (SEQ ID NO: 7); an antibody that binds phosphorylated AKT (SEQ ID NO: 4); and/or an antibody that binds phosphorylated ERK (SEQ ID NO: 8); and at least one secondary antibody that binds to the above noted primary antibodies. Optionally the kit comprises a plurality of these antibodies. In a specific embodiment, the kit includes an antibody specific for S6 ribosomal protein (SEQ ID NO: 1) having a phosphorylated serine residue at position 235 in SEQ ID NO: 1; an antibody specific for AKT (SEQ ID NO: 4) having a phosphorylated serine residue at position 473 in SEQ ID NO: 4; or an antibody specific for ERK (SEQ ID NO: 8) having a phosphorylated threonine residue at position 202 or a phosphorylated tyrosine residue at position 204 in SEQ ID NO: 8.

[0079] Another embodiment of the invention is a kit for characterizing a mammalian glioma tumor or cell, the kit comprising: an antibody that binds PTEN (SEQ ID NO: 5); an antibody that binds phosphorylated S6 ribosomal polypeptide (SEQ ID NO: 1); an antibody that binds EFGR (SEQ ID NO: 7); an antibody that binds phosphorylated AKT (SEQ ID NO: 4); an antibody that binds phosphorylated ERK (SEQ ID NO: 8). Typically the kit further comprises a secondary antibody which binds to one of the primary antibodies directed to these polypeptides. Optionally the kit comprises a plurality of antibodies such as an antibody specific for S6 ribosomal polypeptide (SEQ ID NO: 1) having a phosphorylated serine residue at position 235 in SEQ ID NO: 1, an antibody specific for AKT (SEQ ID NO: 4) having a phosphorylated serine residue at position 473 in SEQ ID NO: 4; or antibody specific for ERK having a phosphorylated threonine residue at position 202 and tyrosine 204 in SEQ ID NO: 8. Optionally the kit further includes an antibody that binds Ki-67 polypeptide (SEQ ID

NO: 9), p-H3 histone polypeptide (SEQ ID NO: 10) or caspase-3 polypeptide (SEQ ID NO: 11).

Typical Protocols Useful To The Practice Of The Invention

5 **[0080]** The methods of the present invention typically utilize antibodies directed to polypeptides in the PI3K/Akt pathway. Illustrative antibody compositions useful in the present invention are anti-phosphoprotein antibodies characterized as containing antibody molecules that specifically immunoreacts with a phosphorylated form of a polypeptide associated with the PI3K/Akt pathway. The polypeptide may be for
10 example, S6, mTOR, FKHR, AKT or PTEN. By "specifically immunoreacts", it is meant that the antibody binds to the phosphorylated form of polypeptide (i.e. is phospho-specific) and does not bind to the unphosphorylated form of the same polypeptide. Consequently, the phosphorylation associated with pathway activation can be examined with such antibodies. Therefore, the antibodies of the invention can
15 distinguish between the phosphorylated and unphosphorylated forms of a polypeptides associated with the PI3K/Akt pathway. Consequently, the phosphorylation associated with pathway activation can be examined with such antibodies. Typically the assays of the invention include immunohistochemical techniques using the antibodies disclosed herein. For example, a sample can be examined for the presence of a biochemical
20 pathway associated phosphorylated polypeptide such as phosphorylated ERK by using an antibody that binds an epitope comprising a phosphorylated threonine residue at position 202 and tyrosine 204 in SEQ ID NO: 8.

1. Antibodies

25 **[0081]** The antibodies useful in the invention may comprise polyclonal antibodies, for example affinity purified polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected
30 in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the appropriate polypeptide epitopes (e.g. a S6 polypeptide (SEQ ID NO: 1) having a phosphorylated serine, threonine or tyrosine residue, a mTOR polypeptide (SEQ ID NO: 2) having a phosphorylated serine, threonine or tyrosine residue, a FKHR polypeptide (SEQ ID NO: 3) having a phosphorylated serine,

threonine or tyrosine residue, a ERK polypeptide (SEQ ID NO: 8) having a phosphorylated serine, threonine or tyrosine residue, a AKT polypeptide (SEQ ID NO: 4) having a phosphorylated serine, threonine or tyrosine residue, or a PTEN polypeptide) or a fusion protein thereof.

5 **[0082]** In addition, it may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant
10 (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

[0083] The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a
15 mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

[0084] The immunizing agent will typically include a phosphorylated S6, mTOR, FKHR, ERK or AKT polypeptide or PTEN polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding,
25 Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the
30 unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

[0085] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell
5 Distribution Center, San Diego, California and the American Type Culture Collection, Rockville, Maryland. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

10 [0086] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against phosphorylated S6, mTOR, FKHR, ERK or AKT polypeptides or PTEN and EGFR polypeptides. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as
15 radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

[0087] After the desired hybridoma cells are identified, the clones may be
20 subcloned by limiting dilution procedures and grown by standard methods (Goding, supra). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal. The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by
25 conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[0088] The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the
30 monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into

host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison et al., *supra*) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

[0089] The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

[0090] *In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

[0091] Reactivity of antibodies with the cognate protein can be established by a number of well known means, including Western blot, immunoprecipitation, ELISA, and FACS analyses. A antibody or fragment thereof can be labeled with a detectable marker or conjugated to a second molecule. Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme.

2. Assays

[0092] The invention provides assays for examining cellular pathways associated with disregulated cell growth. Certain embodiments of the invention include the steps of detecting the presence of phosphorylated S6, mTOR, FKHR, AKT or ERK polypeptides or PTEN and EGFR polypeptides in a tissue. Methods for detecting these polypeptides are well known and include, for example, immunoprecipitation, immunohistochemical analysis, Western blot analysis, molecular binding assays, ELISA, ELIFA and the like.

[0093] Typically the assays of the invention include immunohistochemical techniques. Immunohistochemical techniques as used herein encompasses the use of reagents detecting cell specific markers, such reagents include, for example antibodies. Antibodies, including monoclonal antibodies, polyclonal antibodies and fragments thereof, are often used to identify proteins or polypeptides of interest in a sample. A number of techniques are utilized to label objects of interest according to immunohistochemical techniques. Such techniques are discussed in Current Protocols in Molecular Biology, Unit 14 et seq., eds. Ausubel, et al., John Wiley & Sons, 1995, the disclosure of which is incorporated herein by reference. Typical protocols include staining a paraffin embedded tissue section prepared according to a conventional procedure (see, e.g. U.S. Patent No. 6,631,203).

[0094] Certain embodiments of the invention include tunel assays a markers of apoptosis. Typically, a *TUNEL* assay is performed essentially as follows: the percentage of apoptotic cells are detected by the APO-BRDU terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end-labeling assay (see, e.g. Gavrieli, et al., J. Cell Biol. 119: 493-501) according to manufacturer's instructions (see, e.g. Phoenix Flow Systems, Phoenix, AZ). For further discussions of TUNEL assays useful in methods of the invention see, e.g. Prochazkova et al., Biotechniques 2003 Sep;35(3):528-34; Duan et al., J Pathol. 2003 Feb;199(2):221-8; and Walker et al., J Pathol. 2001 Oct;195(3):275-6.

[0095] Certain embodiments of the invention include caspase-3 assays. Those skilled in the art will appreciate that the caspase-3 assay measures the activation of caspase-3 enzyme, a critical early event of apoptosis induced death (see, e.g. U.S. Patent Application No. 20020159996 and U.S. Patent No. 6,346,607). For further discussions of TUNEL assays useful in methods of the invention see, e.g. Duan et al., J Pathol. 2003 Feb;199(2):221-8; and Walker et al., J Pathol. 2001 Oct;195(3):275-6.

[0096] Throughout this application, various publications are referenced. The disclosures of these publications are hereby incorporated by reference herein in their entireties.

EXAMPLES

EXAMPLE 1: Patient selection and construction of Tissue Microarray:

[0097] All patients participating in this study gave informed consent prior to surgery, in accordance with UCLA Institutional Review Board Policies. Formalin-fixed, paraffin-embedded tissue blocks were taken from 45 patients diagnosed with a glioblastoma at initial surgical resection and treated by the UCLA neuro-oncologist. The

diagnosis was confirmed independently by at least two Neuropathologists. None of the patients were treated prior to removal of the tumor. Three representative 0.6 mm cores were obtained from diagnostic areas of the tumor blocks from each of the primary GBM patients; two from geographically distinct regions of tumor and one from a region of normal brain tissue when available (approximately 2/3 of cases). The cores were then inserted into a grid pattern in a recipient paraffin block using a tissue arrayer. Five-micron sections were cut from the tissue array and immunohistochemistry was performed. Serial sections from the tissue array were used for immunohistochemical analysis. Four tumors had sufficient material on the tissue array for analysis of PTEN, EGFR and EGFRvIII, but lacked sufficient material for analysis of p-Akt, p-mTOR, p-S6, p-FKHR and p-Erk.

EXAMPLE 2: Immunohistochemical Staining

[0098] Sections from the tissue microarray were stained with monoclonal antibodies to PTEN (clone 6H2.1, Cascade Bioscience, Winchester MA), EGFR (clone 31G7, Zymed, San Francisco, CA), EGFRvIII (clone L8A4, a generous gift from Dr. Darrell Bigner), and phosphorylation specific antibodies directed against p-Akt (ser 473) p-FKHR (thr24) /p-FKHRL1 (thr32), p-mTOR (ser 2481), p-S6 ribosomal protein (ser 235/236) and p-44/42 MAP kinase (p-Erk) (thr202/tyr204) (Cell Signaling Technologies, Beverly, MA). Sections were baked at 60°C and de-paraffinized with xylenes and graded ethanols. Heat-induced antigen retrieval was used as follows: for p-Erk, p-Akt, p-mTOR, p-FKHR/FKHRL1 and p-s6, 0.01 M citrate buffer, pH 6 for 25 minutes in a pressure cooker; for PTEN, 0.01M citrate buffer, pH 6 for 16 minutes in a microwave oven; EGFR, pronase (0.03 g/ml of 0.05 M Tris buffer, pH 7.4) at 37°C for 8 minutes and for EGFRvIII, 0.01 M citrate buffer, pH 6 for 25 minutes in a vegetable steamer. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in methanol. Primary antibodies (PTEN at 1:400, EGFR at 1:150, EGFRvIII at 1:400, p-Akt 1:50, p-mTOR 1:50; p-FKHR/FKHRL1 1:50, pS6 1:50 and p-ERK at 1:50) were diluted in Tris buffered saline with 0.1% Tween and applied for 16 hours at 4°C, followed by anti-mouse or anti-rabbit biotinylated immunoglobulins (Vector) at 1:100 dilution for one hour, and finally, avidin-biotin complex (Elite ABC, Vector) for one hour. Negative control slides received normal mouse serum (DAKO) as the primary antibody. Diaminobenzidine tetrahydrochloride was used as the enzyme substrate to visualize

specific antibody localization for PTEN, EGFR and EGFRvIII; Vector NovaRed (Vector) was used for phospho-specific antibodies. Slides were counterstained with Harris hematoxylin.

5 **EXAMPLE 3: Scoring and Interpretation of Immunohistochemistry:**

[0099] *PTEN* - PTEN staining was scored according to a previously established scale of 0-2, in which the vascular endothelium (score of 2) serves as an internal control (see, e.g., Perren et al., Am J Pathol. 157: 1097-103., 2000; Perren et al., Am J Pathol. 155: 1253-60., 1999; Zhou et al., Am J Pathol. 161: 439-47., 2002; Gimm et al., Am J Pathol. 156: 1693-700., 2000). Tumor cells are graded as 2 if their staining intensity is equal to that of the vascular endothelium, 1 if it is diminished relative to the endothelium, and 0 if it is undetectable in the tumor cells and present in the vascular endothelium (see, e.g., Zhou et al., Am J Pathol. 161: 439-47., 2002). This scoring system has been shown to be highly consistent between different cancer cell types, including breast (see, e.g., Perren et al., Am J Pathol. 155: 1253-60., 1999), ovarian (see, e.g., Mutter et al., Cancer Res. 61: 4311-4314., 2001), pancreas (see, e.g., Perren et al., Am J Pathol. 157: 1097-103., 2000) and colon (see, e.g., Zhou et al., Am J Pathol. 161: 439-47., 2002). Two Neuropathologists scored the tumors independently. In addition, tumors were scored by one of the Neuropathologists on two independent occasions. Both the inter-rater, and the intra-rater agreement were greater than 90%.

[0100] *EGFR and EGFRvIII* – Tumors demonstrating strong EGFR immunopositivity in greater than 20% of tumor cells were considered to be positive (see, e.g., Liotta et al., Jama. 286: 2211-4., 2001); tumors demonstrating at least focal moderate to strong immunoreactivity for EGFRvIII were considered positive, as previously reported (see, e.g., Choe et al., Clin Cancer Res. 8: 2894-901., 2002). The inter-rater and intra-rater agreement for EGFR and EGFRvIII were > 90%.

[0101] *Phosphorylation specific antibodies*- Phospho-Akt, mTOR, S6 and FKHR were scored on a scale of 0-2 (0+ no staining, 1+ = mild intensity cytoplasmic staining, and 2+ = strong cytoplasmic staining; staining of 1+ and 2+ were considered positive. The agreement between reviewers, as well as for the same reviewer on independent reviews, was 80% for p-Akt. It was higher for phosphorylated mTOR, S6 and FKHR, ranging from 87% for mTOR to 100% for S6. For phospho-ERK, tumors that focally contained greater than 5% positive nuclear staining were considered positive, as previously reported

(see, e.g., Choe et al., Clin Cancer Res. 8: 2894-901., 2002). The agreement between reviewers, and for the same reviewer on independent reviews, was > 85%.

EXAMPLE 4: Statistical analysis

[0102] The association between markers was analyzed using Fisher's Exact test.
5 The software was available on the Simple Interactive Statistical Website which can be identified with a internet search using the terms "home.clara.net" (<http://home.clara.net/sisa/index.htm>). For analysis of prognostic factors, we excluded 13 patients who did not receive therapy other than surgery. These patients had a poor performance status at the time of diagnosis and elected not to have further therapy. All
10 other patients had received at least standard involved field fractionated radiation therapy. Kaplan-Meier curves were generated to assess the association of variables with time from initial diagnosis to evidence of progression by imaging or clinical features (time to tumor progression) and time from initial diagnosis to death (overall survival). To identify statistically significant differences in time to progression and overall survival, the
15 Wilcoxon two sample test was used.

EXAMPLE 5: Assessment of PTEN/Akt pathway by IHC

[0103] We constructed a tissue microarray consisting of samples from 45 untreated primary GBM patients (Table 1). All of the tumors presented as *de novo* grade IV tumors ("primary GBMs") (see, e.g., Kleihues et al., Neuro-oncol. 1: 44-51., 1999).
20 None of the patients received any radiation or chemotherapy prior to surgical resection. We focused on primary GBMs because they have a high incidence of PTEN mutations and EGFR over-expression (see, e.g., Kleihues et al., Neuro-oncol. 1: 44-51., 1999) and because this enabled us to analyze PI3'K/Akt pathway activation in the absence of prior therapy. The patients ranged in age from 28 to 88 with a median age of 58 (Table 1); all
25 were diagnosed with a GBM on biopsy by at lease two independent Neuropathologists.

[0104] PTEN protein expression was diminished or lost in 17/45 GBMs (38%) (Fig. 1, Table 2). This is in agreement with previous studies that have used DNA-based methods to detect PTEN loss in 30-40% of GBMs (see, e.g., Liu et al., Cancer Res. 57: 5254-7., 1997; Schmidt et al., J Neuropathol Exp Neurol. 58: 1170-83., 1999; Smith et al.,
30 J Natl Cancer Inst. 93: 1246-56., 2001). Akt phosphorylation was significantly associated with diminished PTEN immunohistochemical expression ($p < 0.00001$) (Fig 1., Table 2). PTEN loss was not significantly associated with expression of p-Erk (Table 2), whose activation is independent of PI3'K/Akt signaling. To determine whether Akt activation

correlated with concurrent activation of downstream effectors, we used phosphorylation specific antibodies directed against mTOR, FKHR and S6. mTOR and FKHR are directly phosphorylated by Akt (see, e.g., Vivanco et al., Nat Rev Cancer. 2: 489-501., 2002; Hidalgo et al., Oncogene. 19: 6680-6686., 2000); S6 is phosphorylated by p70 S6 kinase, which is itself a target of Akt (see, e.g., Blume-Jensen et al., Nature. 411: 355-365., 2001). Akt activation was significantly associated with expression of p-mTOR (p=0.04) and p-FKHR (p=0.006)(Table 3). Akt activation was also correlated with strong S6 phosphorylation (2+) (p=0.001), although weaker S6 phosphorylation (1+) was also detected in Akt- negative tumors (Table 3). This latter result is not surprising considering that S6 can be activated by Erk in a PI3'K/Akt independent fashion (see, e.g., Iijima et al., J Biol Chem. 277: 23065-75., 2002; Shi et al., J Biol Chem. 277: 15712-20., 2002). Taken together, these results provides evidence that PI3'K/Akt pathway activation can be detected in routinely processed paraffin-embedded biopsy samples, and demonstrate that PTEN protein loss is associated with PI3'K/Akt pathway activation in GBMs.

EXAMPLE 6: Akt pathway activation in GBMs lacking PTEN protein loss: assessment of EGFR/EGFRvIII-mediated signaling

[0105] PTEN loss did not appear to be the only route to Akt activation; expression of p-Akt and downstream effectors p-mTOR, p-FKHR and p-S6 was also detected in 28% of GBMs with no immunohistochemical PTEN loss (Table 2). Because the PI3'K/Akt pathway can be activated by EGFR signaling, we analyzed EGFR and EGFRvIII expression and assessed their association with PI3'K/Akt pathway activation in the setting of normal PTEN immunohistochemical staining. EGFR immunopositivity was detected in 60% of GBMs (Fig. 2), in line with previous reports (see, e.g., Smith et al., J Natl Cancer Inst. 93: 1246-56., 2001; Watanabe et al., Brain Pathol. 6: 217-23; discussion 23-4., 1996; Ekstrand et al., Proc Natl Acad Sci U S A. 89: 4309-13., 1992; Frederick et al., Cancer Res. 60: 1383-7., 2000; Hayashi et al., Brain Pathol. 7: 871-5., 1997; Nagane et al., Cancer Lett. 162 Suppl: S17-S21., 2001; Nishikawa et al., Proc Natl Acad Sci U S A. 91: 7727-31., 1994; Wikstrand et al., Cancer Res. 57: 4130-40., 1997). Immunohistochemical expression of the constitutively active mutant EGFRvIII was detected in 56% of EGFR positive tumors (44% of tumors overall) (Fig. 2) (Smith et al., J Natl Cancer Inst. 93: 1246-56., 2001; Nagane et al., Cancer Lett. 162 Suppl: S17-S21., 2001; Nishikawa et al., Proc Natl Acad Sci U S A. 91: 7727-31., 1994; Wikstrand et al., Cancer Res. 57: 4130-40., 1997). Strongly activated Akt (2+ staining) was not detectable

in GBMs with normal PTEN immunohistochemical expression that lacked EGFR and EGFRvIII expression (Table 2). In contrast, 36% of GBMs with normal PTEN immunohistochemical expression that also co-expressed EGFR and EGFRvIII stained strongly for activated Akt ($p=0.06$) (Table 2). Although the subset of tumors was small, co-expression of EGFRvIII along with EGFR appeared to be required for strong Akt activation (2+ staining)(Table 2). These results provides evidence that co-expression of EGFR and EGFRvIII can promote Akt activation in GBMs with normal PTEN protein expression. Consistent with this, downstream activation of mTOR, S6 and FKHR were also significantly more likely to be strongly activated (2+ staining) in GBMs with normal PTEN expression when EGFR and EGFRvIII were co-expressed ($p<0.002$).

[0106] In addition to the Akt pathway, EGFR, and EGFRvIII can also activate Erk. Therefore, we determined whether Erk phosphorylation was associated with EGFR and EGFRvIII expression. Overall, Erk phosphorylation was detected in 51% of GBMs. More importantly, expression of phosphorylated Erk was significantly associated with EGFR expression ($p=0.007$)(Fig. 2; Table 4). Phosphorylated Erk was expressed in 75% of EGFR+/EGFRvIII negative GBMs and 88% of EGFR+/EGFRvIII positive GBMs.

EXAMPLE 7: Prognostic implications of Akt and Erk pathway activation

[0107] Previous studies have not shown a clear prognostic implications for PTEN loss, EGFR over-expression or EGFRvIII expression in GBMs. In line with this, we found no statistically significant association between PTEN protein loss, EGFR or EGFRvIII expression and either time to progression or overall survival. In contrast, coordinate pathway activation appeared to have prognostic implications. Expression of p-Akt was not significantly associated with survival or progression. In contrast, activation of the downstream pathway, as detected by concurrent phosphorylation of mTOR, FKHR and S6, was significantly associated with both a shorter time to progression ($p=0.002$) and a decreased overall survival ($p=0.02$). This finding may reflect a contribution from additional inputs downstream of Akt, such as Erk-mediated activation of S6 kinase and nutrient-mediated activation of mTOR. Alternatively, this panel of three phospho-specific antibodies may be a more sensitive method to detect Akt pathway activation than a single phospho-Akt antibody alone. Erk activation was also significantly associated with more rapid progression and diminished overall survival in this subset of primary GBM patients (<0.04) (Table 5). these findings are the first demonstration that pathway activation has an impact on tumor progression in GBM patients.

EXAMPLE 8: Kinase Inhibitors Akt and Erk pathway activation

5 [0108] Figures 3A and 3B provide an illustration of the interaction between members of the PI3K/Akt pathway and kinase inhibitors.

10 [0109] Figure 3A shows that rapamycin inhibits S6 phosphorylation in glioblastoma in vivo. In particular, Figure 3A provides data from an analysis of a cohort of patients on a rapamycin clinical trial. This data shows that a substantial reduction in S6 phosphorylation relative to the initial biopsy was detected in the tumor in the majority of patients treated with rapamycin for 5 days prior to undergoing surgical resection. Control patients showed a uniformly high level of S6 phosphorylation. This data provides evidence that rapamycin inhibited mTOR signaling at the level of S6 phosphorylation in the majority of glioblastoma patients. In addition, this data illustrates how the detection of pathway activation by immunohistochemistry (IHC) correlates with
15 detection by western blotting.

20 [0110] Figure 3B shows that the rapamycin-mediated inhibition of S6 phosphorylation correlates with diminished tumor proliferation. In this Figure, Ki-67, a marker of cellular proliferation was used to assess whether rapamycin-mediated inhibition of S6 had an effect on tumor growth. This data provides evidence that the rapamycin-mediated inhibition of mTOR signaling at the level of S6 phosphorylation correlated with diminished tumor cell proliferation.

25 [0111] The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any that are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing
30 from the true scope and spirit of the invention.

TABLES

Table 1 Patient Characteristics

Clinical Characteristics	#
Sex	
M	29
F	16
Age (years)	
median	58
mean	58
range	28-88
Time to progression (days)	
median	183
mean	227
range	54-1006
Survival (days)	
median	412
mean	427
range	86-1794

Table 2 Association between PTEN expression and Akt pathway activation

	p-Akt		p-mTOR		p-FKHR		p-S6		p-ERK					
	0	1	2	0	1	2	0	1	2	0	1	2	+	-
PTEN-	2	1	13	3	4	10	2	2	12	4	3	10	8	7
PTEN+	18	3	4	6	8	11	10	2	13	5	7	12	16	8
p-value			0.00001			ns			ns			ns		ns
PTEN+/EGFR- /EGFRvIII-	6	2	0	5	2	0	7	0	1	5	2	0	nd	nd
PTEN+/EGFR+/EGFRvI II-	3	1	0	0	1	2	1	2	1	0	1	3	nd	nd
PTEN+/EGFR+/EGFRvI II+	7	0	4	0	3	9	2	1	10	0	3	10	nd	nd
p-value			0.06			0.001			0.002			0.001		nd

5

Table 3 Association between Akt activation and downstream signaling

	p- mTOR 0	p- mTOR 1	p- mTOR 2	p- value	p- FKHR 0	p- FKHR 1	p- FKHR 2	p- value	p- S6 0	p- S6 1	p- S6 2	p-value
p- Akt-	6	7	7		10	1	9		6	7	7	
p- Akt+	1	5	14	0.04	1	3	16	0.006	4	3	13	0.15 (*0.003)

Table 4 Univariate analysis between EGFR receptor status and downstream signalling.

	Pearson Correlation	p-value
EGFR		
EGFRvIII	0.31	0.04
p-Erk	0.34	0.03
p-Akt	0.07	0.67
p-FKHR	0.25	0.12
p-mTOR	0.24	0.13
p-S6	0.3	0.06
EGFRvIII		
p-FKHR	0.33	0.04
p-mTOR	0.31	0.06
p-S6	0.3	0.06

Table 5 Univariate association between pathway activation and prognosis

	Time to progression (days)	p-value	Survival (days)	p-value
p-Erk+	148		356	
p-Erk-	263	0.05	488	0.02
p-mTOR+/p-FKHR+/p-S6+	142	0.002	357	0.02
p-mTOR-/p-FKHR-/p-S6-	308		528	
p-Akt+	176	NS	358	NS
p-Akt-	238		419	
PTEN +	153	NS	438	NS
PTEN -	212		346	
EGFR+	151	NS	385	NS
EGFR-	243		412	
EGFRvIII+	135	NS	420	NS
EGFRvIII-	230		351	

TABLE 6 POLYPEPTIDE SEQUENCES

For convenience, Table 6 provides the sequences, accession numbers and illustrative references for the well known polypeptides discussed herein. In certain sequences in this Table, illustrative residues that are typically phosphorylated during pathway signalling are shown in boldface type.

S6 (NP 001001, gi:17158044) 249 amino acids

See, e.g. Pata et al., Gene 121 (2), 387-392 (1992)

MKLNISFPATGCQKLI EVDDERKLRTFYEKRMATEVAADALGEEWKGYVVRISSGND
KQGFPMKQGVLT HGRVRLLLSKGHSCYRPRRTGERKRKSVRGCIVDANLSVLNLVIV
KKGEKDIPGLTDTTVPRLGPKRASRIRKLFNLSKEDDVRQYVVRKPLNKEGKKPRT
KAPKIQRLVTPRVLQHKRRRIALKKQRTKKNKEEAAEYAKLLAKRMKEAKEKRQEIQI
AKRRRLSSLRASTSKSESSQK (SEQ ID NO: 1)

m-TOR (NP 004949, gi:4826730) 2549 amino acids

See, e.g. Brown et al., Nature 369 (6483), 756-758 (1994)

MLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQ
EESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNL
LPSNDPVVMEMASKAIGRLAMAGDTFTA EYVEFEVKRALEWL GADRNEGRRHAAVLV
LRELAISVPTFFFQVQVQFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREP KEM
QKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREE
MEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYS SHQGL
MGFGTSPSPAKSTLVESRCCDLMEEFKDQVCQWVLKCRNSKNSLIQMTILNLLPRL
AAFRPSAFTDTQYLQDTMNHVLS CVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVL
DIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGL
SPALTAVLYDL SRQIPQLKKDIQDGLLKMLS LVLMMHKPLRHPGMPKGLAHQLASPGL
TTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCS
RLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFD
AHLAQAE NLQALFVALNDQVFEIRELAICTVGR LSSMNP AFVMPFLRKMLIQILTEL
EHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPI LKALILKLKDPDPDPNPGVINNV
LATIGELAQVSGLEMRKWVDELFI IIMDMLQDSSLLAKRQVALWTLGQLVASTGYVV
EPYRKYP TLLLEVLLNFLKTEQNQGT RREAIRVLGLLGALDPYKHKVNIGMIDQSRDA
SAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHT
MVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSH
IRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFM
HDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFD APEAPLPSRKA ALETVD
RLTESLDFTDYASRIIHPIVRTLDQSP ELRSTAMDTLSSLVFQLGKKYQIFIPMVNK
VLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGP
MKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQA YN
PMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSD
KGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILES LISINNKLQQ
PEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMR
CLEALGEWGQLHQQCCEKWTLVNDETQAKMARM AAAAAWGLGQWDSMEEYTCMI PRD
THDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMV SCHML
SELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVS PHEDMRTW
LKYASLCGKSGRLALAHKTLVLLLGVDP SRQLDHPLPTVHPQV TYAYMKNMWKSARK

IDAFQHQHFVQTMQQQAQHAIATEDQQHKQELHKL MARCFLKLGEWQLNLQGINES
 TIPKVLQYYSAATEHDRSWYKAHHAWVMNFEAVLHYKHQNQARDEKKKLRHASGAN
 ITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDL SKTLLMYT
 VPAVQGFFRSISLSRGNNLQDTRLRVLT LWFDYGHWPDVNEALVEGVKAIQIDTWLQV
 5 IPQLIARIDTPRPLVGR LIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKIL
 KNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKG MFEVLE
 PLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFR
 RISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSK
 QRPRKLTLMGSGNHEFVFLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQ
 10 RYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTL
 MQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRTNYTRSLAVMSVMGYILGLG
 DRHPSNMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDG
 NYRITCHTVMEVLREHKDSVMVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSA
 GQSVEILDGVELGEPAHKKTGTTVPESIH SFIGDLVKPEALNKKAIQIINRVRDKL
 15 TGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFW (SEQ ID NO: 2)

FORKHEAD (NP 002006, gi:9257222) 655 amino acids

See, e.g. Anderson et al., Genomics 47 (2), 187-199 (1998)

20 MAEAPQVVEIDPDFEPLPRPRSC TWPLPRPEFSQSNSATSSPAPSGSAAANPDAAAG
 LPSASAAAVSADFM SNLSLLEESDFPQAPGSVAAAVAAAAAATGGLCGDFQGPE
 AGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNLSYADLITK
 AIESSAEKRLTLSQIYEW MVKSVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQN
 25 EGTGKSSWMLNPEGKSGKSPRRRAASMDNNSKFAKRSRAAKKASLQSGQEGAG
 DSPGSQFSKWPASPGSHSND DFDNWSTFRPRTSSNASTISGR LSPIMTEQDDLGECD
 VHSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQSSPGTMM
 QQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQTLQDNKSSYGGMSQYN
 CAPGLLKELLTSDSPPHNDIMTPVDPGVAQPN SRVLGQNVMMGPNSVMSTYGSQASH
 30 NKMMNPSSHTHPGHAQQTS AVNGRPLPHTVSTMPHTSGMNRLTQVKTPVQVPLPHPM
 QMSALGGYSSVSSCNGYGRMGL LHQEKLPDLDGMFIERLDCDMESIIRNDLMDGDT
 LDFNFDNVLPNQSFPHSVKTTTHSWVSG (SEQ ID NO: 3)

AKT (NP 005154 gi:4885061) 480 amino acids

See, e.g. Staal, S.P., Proc. Natl. Acad. Sci. U.S.A. 84 (14), 5034-5037 (1987)

40 MSDVAIVKEGWLHKG EYIKTWRPRYFLLKNDGTFIGYKERPQDQDQREAPLNNFSV
 AQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEERE EWTTAIQTVADGLKKQE
 EEEMDFRSGSPSDNSGAEEMEVS LAKPKHRVTMNEFEY LKLLGKGTFGKVILVKEKA
 TGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVME
 YANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVYRDLKLENLMLDKD
 GHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEM
 MCGRLPFYNQDHEKLFELI LMEEIRFPRTLGP EAKSLLSGLLKKDPKQRLGGGSEDA
 KEIMQHRFFAGIVQH VYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDD
 45 SMECVDSERRPHFPQFSYSASSTA (SEQ ID NO: 4)

PTEN (NP 000305, gi:4506249) 403 amino acids

See, e.g. Li et al., Science 275 (5308), 1943-1947 (1997)

50 MTAIIKEIVSRNKRRYQEDGFDL DLTYYIPNIIAMGFPAERLEGVYRNNIDDVVRFL
 DSKHKNHYKIYNLCAERHYDTAKFNCRVAQY PFEDHNPPQLELIKPFCELDLQWLSE

DDNHVAAIHCKAGKGRGTGVMICAYLLHRGKFLKAQEALDFYGEVTRTRDKKGV TIP SQ
RRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSN
SGPTRREDKFMFYFEFPQPLPVCGLDIKVEFFHKQNKMLKKDKMFHFWNTFFIPGP
TSEKVENGLCDQEIDSICSIERADNDKEYLVLTLTKNLDLKDANKDKANRYFSPNFK
5 VKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDDTSDPENEPFDEDQHTQ
ITKV (SEQ ID NO: 5)

FKHRL1 (O43524, gi:8134467) 673 amino acids

See, e.g. Hillion et al., Blood 90 (9), 3714-3719 (1997)

10 MAEAPASPAPLSPLEVELDPEFEPQSRPRSCWPLQRPQLQASPAKPSGETAADSMI
PEEEDDEDEDGGGRAGSAMAIGGGGGSGTLGSGLLLED SARVLAPGGQDPGSGPAT
AAGGLSGGTQALLQPQQPLPPPQPGAAGGSGQPRKCSSRRNAWGNLSYADLITRAIE
SSPDKRLTLSQIYEWVRCVPYFKDKGDSNSSAGWKNSIRHNLSLHSRFRMVQNEGT
15 GKSSWWIINPDGGKSGKAPRRRAVSMDNSNKYTKSRGRAAKKKAALQTAPESADDSP
SQLSKWPGSPTSRSSELDATWDFRSRTNSNASTVSGRLSPIMASTELDEVQDDAP
LSPMLYSSASLSPSVSKPCTVELPRLTDMAGTMNLDGLTENLMDDLLDNITLPPS
QPSPGTGGLMQRSSSFYTTKSGSLGSPSTSSFNSTVFGPSSLNSLRQSPMQTIQENKP
ATFSSMSHYGNQTLQDLLTSDSLSHSDVMMTQSDPLMSQASTAVSAQNSRRNVMLRN
20 DPMMSFAAQPNQGSVLNQNLLHHQHQTQ GALGGSRALNSNSVSNMGLSESSSLGSAKH
QQQSPVSQSMQTLSDSLSGSSLYSTSANLPVMGHEKFPSDLDLDMFNGLSECDMESI
IRSELMDADGLDFNFDLISTQNVVGLNVGNFTGAKQASSQSWVPG (SEQ ID
NO: 6)

25 **EGFR (NP 005219, gi:29725609) 1210 amino acids**

See, e.g. Tam et al., Nature 309 (5967), 418-425 (1984)

MRPSGTAGAALLALLAALCPASRALEEKVKCQGTSNKLTQLGTFEDHFLSLQRMFNN
CEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLNLQIIRGNMYYE
30 NSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSD
FLSNMSMDFQNHGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSP
SDCCHNQCAAGCTGPRESCLVCRKFRDEATCKDTCPLMLYNPTTYQMDVNPEGKY
SFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGI
GEFKDLSINATNIKHFNCTSSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVK
35 EITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEI
SDGDVIIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPE
GCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPRFVENSECIQCHPECLPQAMNIT
CTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYG
CTGPGLEGCPNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTRLRRLQ
40 ERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIP
VAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCL
LDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRLVHRDLAARNVLVKTPOHVKITD
FGLAKLLGAEEKEYHAEGGKVPKWMALLESILHRIYTHQSDVWSYGVTVWELMTFGS
KPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFS
45 KMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDVDVDADEYLI PQQGFSS
PSTSRTPLLSSLSATSNNSTVACIDRNLQSCPIKEDSFLQRYSSDPTGALTEDSID
DTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
TVQPTCVNSTFDSPAHWAKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEY
LRVAPQSSEFIGA (SEQ ID NO: 7)

50 **p-ERK (XP 055766, gi:20562757) 379 amino acids**

See, e.g. Butch et al., J Biol Chem. 1996 Feb
23;271(8):4230-5.

MAAAAAQGGGGGEPRRTEGVGPGVPGEVEMVKGQPFVDVGPRYTQLQYIGEGAYGMVS
 SAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRASTLEA
 MRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSN
 5 LLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWRAPPEIMLSKGYTKSIDI
 WSVGCILAEMLSNRPIFPKGHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLP
 SKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPLYEQYYDPTDEPVA
 EEPFTFAMELDDLPKERLKELEIFQETARFQPGVLEAP (SEQ ID NO: 8)

10 **Ki-67 (CAA46519, gi:415819) 3256 amino acids**
 See, e.g. Schluter et al., J. Cell Biol. 123 (3), 513-522
 (1993)

MWPTRRLVTIKRSGVDGPHFPLSLSTCLFGRGIECDIRIQLPVVSKQHCKIEIHEQE
 15 AILHNFSSTNPTQVNGSVIDEPVRLKHGDVITIIDRSFRYENESLQNGRKSTEFPRK
 IREQEPARRVSRSSFSSDPDEKAQDSKAYSKITEGKVSGNPQVHIKNVKEDSTADDS
 KDSVAQGTNNVHSSSEHAGRNGRNAADPISGDFKEISSVKLVSRYGELKSVPTTQCLD
 NSKKNESPFWKLYESVKKELDVKSQKENVLQYCRKSGLQTDYATEKESADGLQGETQ
 LLVSRKSRPKSGSGHAVAEPASPEQELDQNGKGRDVESVQTPSKAVGASFPLYEP
 20 AKMKTVPQYSQQQNSPQKHKNKDLYTTGRRESVNLGKSEGFKAGDKTLTPRKLSTRN
 RTPAKVEDAADSATKPENLSSKTRGSIPTDVEVLPTETEIHNPFLLTLWLTVQVERKI
 QKDSLKPEKLGTTAGQMCSGLPGLSSVDINNFGDSINESEGIPLKRRRVSGGHLR
 PELFDENLPPNTPPKRGEAPTKRKSVMHTPPVLKKI I KEQPQPSGKQESGSEIHVE
 VKAQSLVISPPAPSPRKTTPVASDQRRRSCKTAPASSSKSQTEVPKRGGERVATCLQK
 25 RVSISRSQHDILQMICSKRRSGASEANLIVAKSWADVVKLGAKQTQTKVIKHGPQRS
 MNKRQRRPATPKKPVGEVHSQFSTGHANSPTIIIGKAHTEKVHVPARPYRVLNNFI
 SNQKMDFKEDLSGIAEMFKTPVKEQPQLTSTCHIAISNSENLLGKQFQGTDSGEEPL
 LPTSESGGNVFFSAQNAAKQPSDKCSASPPLRRQCIRENGNVAKTPRNTYKMTSLE
 TKTSDTETEPSKTIVSTVNRSRSTEFNRNIQKLPVESKSEETNTEIVECILKRGQKAT
 30 LLQQRREGEMKEIERPFETYKENIELKENDEKMKAMKRSRTWGQKCAPMSDLTDLKS
 LPDTELMKDTARGQNLQTDHAKAPKSEKGIITKMPQSLQPEPINTPTHTKQQLK
 ASLGKVGKVEELLAAGVGFTRTSGETTHTHRETAGDGKSIIRTFKESPKQILDPAARVT
 GMKKWPRTPKEEAQSLEDLAGFKELFQTPGPSEESMTDEKTTKIACKSPPPESVDTP
 TSTKQWPKRSLRKADVEEEFLALRKLTSPSAGKAMLTTPKPAAGDEKDIKAFMGTPVQK
 35 LDLAGTLPGSKRQLQTPKEKAQALEDLAGFKELFQTPGHTEELVAAGKTTKIPCDSP
 QSDPVDTPSTKQRPKRSIRKADVEGELLACRNLMPSAGKAMHTPKPSVGEEKDII
 FVGTPVQKLDLTENLTGSKRRPQTPKEEAQALEDLTGFKELFQTPGHTEEEVAAGKT
 TKMPCESSPPESADTPTSTRRQPKTPLEKRDVQKELSALKKLTQTSGETTHTDKVP
 GEDKSINAFRETAKQKLDPAASVTGSKRHPKTKEKAQPLEDLAGWKELFQTPVCTDK
 40 PTTHEKTTKIACRSQPDPTPTSSSKPQSKRSLRKVDVEEEFFALRKRTSPSAGKAMH
 TPKPAVSGEKNIYAFMGTPVQKLDLTENLTGSKRRLQTPKEKAQALEDLAGFKELFQ
 TRGHTEESMTNDKTAKVACKSSQPDLDKNPASSKRRLKTSLGKVGKVEELLAAGKLT
 QTSGETTHTHTEPTGDGKSMKAFMESPKQILDSAASLTGSKRQLRTPKGKSEVPEDL
 AGFIELFQTPSHTKESMTNEKTTKVSYRASQPDLDPTPTSSKPQPKRSLRKADTEEE
 45 FLAFRKQTPSAGKAMHTPKPAVGEEKDINTFLGTPVQKLDQPGNLPGSNRRQLQTRKE
 KAQALEELTGRELQFQTPCTDNPTADEKTTKILCKSPQSDPADTPTNTKQRPKRS
 KKADVEEEFLAFRKLTPSAGKAMHTPKAAVGEEKDINTFVGTPVEKLDLLGNLP
 RRPQTPKEKAKALEDLAGFKELFQTPGHTEESMTDDKITEVSCKSPQPDVKTPTSS
 KQRLKISLGKVGKVEEVLVPGKLTQTSKTTQTHRETAGDGKSIKAFKESAKQMLDP
 50 ANYGTGMRWPRTPKKEAQSLEDLAGFKELFQTPDHTEESTTDDKTTKIACKSPPE
 SMDTPTSTRRRPKTPLGKRDI VEELSALKQLTQTTHTDKVPGDEDKGINVFRETAKQ
 KLDPAASVTGSKRQPRTPKGKAQPLEDLAGLKELFQTPVCTDKPTTHEKTTKIACRS
 PQPDVGTPTIFKPQSKRSLRKADVEEESLALRKRTPSVGKAMDTPKPAAGDEKDMK

AFMGTPVQKLDLPGNLPGSKRWPQTPKEKAQALEDLAGFKELFQTPGTDKPTTDEKT
TKIACKSPQPDVDTASTKQRPKRNLKADVEEEFLALRKRTPSAGKAMDTPKPAV
SDEKNINTFVETPVQKLDLLGNLPGSKRQPQTPKEKAEALEDLVGFKELFQTPGHTE
ESMTDDKITEVSCSKSPQESFKTSRSSKQRLKIPLVKVDMKEEPLAVSKLRTSGET
5 TQTHTEPTGDSKSIKAFKESPKQILDPAASVTGSRRQLRTRKEKARALEDLVDFKEL
FSAPGHTEESMTIDKNTKIPCKSPPELTDATSTKRCPKTRPRKEVKEELSAVERL
TQTSQGQSTHTHKEPASGDEGIKVLKQRAKKPNPVEEPPSRRRPRAPKEKAQPLEDL
AGFTELSETSGHTQESLTAGKATKIPCESPPLEVVDTTASTKRHLRTRVQKVQVKEE
PSAVKFTQTSGETTDADKEPAGEDKGIKALKESAKQTPAPAASVTGSRRRPRAPRES
10 AQAIEDLAGFKDPAAGHTEESMTDDKTTKIPCKSSPELEDATSSKRRPRTRAQKVE
VKEELLAVGKLTQTSGETTHTDKEPVGEGKGTAKFKQPAKRNVD AEDVIGSRRQPRA
PKEKAQPLEDLASFQELSQTPGHTEELANGAADSFTSAPKQTPDSGKPLKISRRVLR
APKVEPVGDVSTRDPVKSQSKSNTSLPPLPFKRGGGKDGSVTGKRLRCMPAPEEI
VEELPASKKQRVAPRARGKSSEPVVIMKRSRLRTSAKRIEPAEELNSNDMKTNKEEHK
15 LQDSVPENKGISLRSRRQDKTEAEQQITEVFVLAERIEINRNEKKPMKTSPEMDIQN
PDDGARKPIPRDKVTENKRCLRSARQNESSQPKVAEESGGQSAKVLMOQNQKGKGEA
GNSDSMCLRSRKTQSQAASTLESKSVQRVTRSVKRCANPKKAEDNVCVKKITTRS
HRDSEDI (SEQ ID NO: 9)

20

p-H3 Histone (AAH38989, gi:25058578) 136 amino acids

See, e.g. Strausberg et al., Proc. Natl. Acad. Sci.
U.S.A. 99 (26), 16899-16903 (2002)

25

MARTKQTARKSTGGKAPRKQLATKAARKSAPSTGGVKKPHRYRPGTVALREIRRYQK
STELLIRKLPFQRLVREIAQDFKTDLRFQSAAGALQEASEAYLVGLFEDTNLCAIH
AKRVTIMPKDIQLARRIRGERA (SEQ ID NO: 10)

30

Caspase-3 (P42574, gi:1169072) 277 amino acids

See, e.g. Goldberg et al., Nat. Genet. 13 (4), 442-449
(1996)

35

MENTENSVDSKSIKNLEPKIIHGSESMDSGISLDNSYKMDYPEMGLCIIINNKNFHK
STGMTSRSGTDVDAANLRETFRNLYEVNRKNDLTREEIIVELMRDVSKEDHSKRSSF
VCVLLSHGEEGIIIFGTNGPVDLKKITNFFRGDRCSLTGKPKLFIIQACRGTELDG
IETDSGVDDDMACHKIPVDADFLYAYSTAPGYYSWRNSKDGSWFIQSLCAMLKQYAD
KLEFMHILTRVNRKVATEFESFSFDFATFHAKKQIPCIVSMLTKELYFYH (SEQ ID
NO: 11)

40

45